https://trial.medpath.com/news/therini-bio-s-thn391-shows-promise-in-phase-1a-trial-for-neurodegenerative-diseases 2025-04-29T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fate-therapeutics-to-showcase-innovative-off-the-shelf-car-t-cell-platform-at-asgct-annual-meeting 2025-04-29T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncocyte-s-blood-based-transplant-rejection-assay-shows-long-term-clinical-validity-in-13-year-study 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-introduces-xm-liquid-biopsy-assay-to-monitor-immunotherapy-response-in-advanced-solid-tumors 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/prometheus-laboratories-unveils-groundbreaking-pre-therapy-test-for-ibd-biologic-response-prediction 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alxn1840-shows-promising-long-term-efficacy-and-safety-for-wilson-disease-at-easl-2025 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bdr-pharmaceuticals-plans-100-million-u-s-expansion-to-boost-global-footprint 2025-04-29T07:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/scaleready-awards-g-rex-grants-to-advance-novel-car-t-cell-therapy-manufacturing 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-with-psv359-in-perspective-therapeutics-phase-1-2a-trial-for-fap-a-positive-solid-tumors 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-to-showcase-ai-powered-real-world-oncology-data-research-at-ispor-2025 2025-04-29T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/community-engagement-emerges-as-critical-bridge-between-cancer-research-and-policy-development 2025-04-29T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-shift-in-iga-nephropathy-treatment-novel-targeted-therapies-address-disease-mechanisms 2025-04-29T02:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-treatment-approaches-for-relapsed-refractory-follicular-lymphoma-navigating-third-line-therapy-options 2025-04-29T02:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-s-gene-therapy-demonstrates-sustained-efficacy-in-knee-osteoarthritis-trial 2025-04-29T01:56:45+00:00 hourly 0.9 https://trial.medpath.com/news/embark-trial-testosterone-levels-recover-in-most-men-after-prostate-cancer-treatment-suspension 2025-04-29T01:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/stablepharma-begins-phase-1-trial-of-world-s-first-fridge-free-tetanus-diphtheria-vaccine 2025-04-29T01:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/deepull-raises-eur50-million-in-series-c-to-advance-rapid-sepsis-diagnostic-technology 2025-04-29T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-expands-can10-development-to-target-treatment-resistant-atopic-dermatitis 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acc-recommends-first-line-obesity-medications-as-prescribing-disparities-persist-for-semaglutide-and-tirzepatide 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/invikafusp-alfa-demonstrates-promising-activity-in-immune-checkpoint-inhibitor-resistant-solid-tumors 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-cell-therapy-shows-100-response-rate-in-refractory-cd30-lymphoma-patients 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transverse-medical-secures-over-10m-in-series-b2-funding-to-advance-stroke-prevention-technology 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-bioinvent-s-bi-1808-for-cutaneous-t-cell-lymphoma 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/capsida-biotherapeutics-advances-novel-gene-therapies-for-cns-disorders-ahead-of-asgct-2025 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fyr-partners-with-mayo-clinic-to-develop-blood-based-biomarkers-for-parkinson-s-disease-using-ai-enabled-platform 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/frontier-medicines-presents-breakthrough-data-on-fmc-220-first-in-class-p53-y220c-activator-for-cancer-treatment 2025-04-28T22:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/oramed-pharmaceuticals-invests-36-9-million-in-alpha-tau-medical-to-advance-cancer-radiation-therapy 2025-04-28T22:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-immunotherapy-trial-aims-to-reprogram-immune-system-in-type-1-diabetes 2025-04-28T22:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-tar-200-shows-promising-results-in-bcg-unresponsive-bladder-cancer-trial 2025-04-28T22:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/michigan-senate-approves-prescription-drug-affordability-board-to-combat-rising-medication-costs 2025-04-28T21:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-appoints-david-l-hallal-as-ceo-strengthens-leadership-team-ahead-of-apitegromab-launch-for-sma 2025-04-28T20:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/histosonics-histotripsy-system-achieves-90-local-tumor-control-at-12-months-in-liver-cancer-trials 2025-04-28T20:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-breakthrough-could-replace-traditional-cancer-treatments-in-select-patients 2025-04-28T20:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-secures-key-chinese-patent-for-covid-19-treatment-rhb-107 2025-04-28T19:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/pharmasyntez-to-launch-three-innovative-drugs-with-blockbuster-potential-in-2025-2026 2025-04-28T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-to-launch-sanofi-s-beyfortus-in-india-for-rsv-prevention-in-infants 2025-04-28T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/cg-oncology-s-bladder-cancer-drug-shows-promising-durability-in-phase-3-trial 2025-04-28T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/yale-s-experimental-cancer-vaccine-shows-remarkable-success-in-canine-clinical-trials 2025-04-28T19:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/ankyra-therapeutics-reports-promising-phase-1-data-for-anchored-il-12-drug-conjugate-in-solid-tumors 2025-04-28T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/g8-frailty-assessment-tool-predicts-docetaxel-tolerability-in-metastatic-prostate-cancer 2025-04-28T19:00:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ai-model-progrxn-bca-significantly-improves-nmibc-progression-risk-prediction 2025-04-28T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bms-986365-shows-promise-in-phase-3-trial-for-advanced-prostate-cancer-resistant-to-standard-therapies 2025-04-28T16:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-s-ruvidar-shows-promise-as-dub-inhibitor-in-cancer-treatment-breakthrough 2025-04-28T16:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-immunochemotherapy-shows-promising-results-in-locally-advanced-oral-squamous-cell-carcinoma 2025-04-28T16:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-unveils-loop-ai-powered-platform-revolutionizes-oncology-target-discovery 2025-04-28T16:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-delcath-s-hepzato-for-phase-2-trial-in-liver-dominant-metastatic-breast-cancer 2025-04-28T16:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/be-biopharma-to-present-promising-nonclinical-data-for-novel-b-cell-therapy-in-hypophosphatasia-treatment 2025-04-28T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/metrion-biosciences-unveils-breakthrough-nav1-9-screening-assay-to-accelerate-non-opioid-pain-therapeutics-development 2025-04-28T16:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-to-present-new-zymfentra-r-data-for-ibd-management-at-2025-digestive-disease-week 2025-04-28T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-initiates-phase-1-trial-combining-ziftomenib-with-imatinib-for-advanced-gist-treatment 2025-04-28T16:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/cellectis-advances-gene-editing-with-non-viral-talen-technology-and-tale-base-editors-at-asgct-2025 2025-04-28T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/spero-therapeutics-appoints-esther-rajavelu-as-president-and-chief-executive-officer 2025-04-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/anthem-blue-cross-and-blue-shield-approves-coverage-for-reactiv8-neurostimulation-therapy-for-chronic-low-back-pain 2025-04-28T15:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/tg-c-shows-promise-as-first-disease-modifying-therapy-for-knee-osteoarthritis-with-15-year-safety-data 2025-04-28T15:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-surpasses-2-2-billion-in-2025-contract-orders-expands-global-biomanufacturing-capacity 2025-04-28T14:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-to-acquire-springworks-therapeutics-in-3-9-billion-deal-for-rare-disease-portfolio 2025-04-28T14:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-to-acquire-antev-for-75-million-gaining-novel-gnrh-antagonist-for-prostate-conditions 2025-04-28T14:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-lenire-device-shows-91-5-success-rate-in-real-world-tinnitus-treatment-study 2025-04-28T14:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-secures-600-million-non-dilutive-funding-from-oberland-capital-for-rare-disease-drug-development 2025-04-28T14:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/talus-bio-unveils-promising-preclinical-data-on-novel-transcription-factor-inhibitors-at-aacr-2025 2025-04-28T13:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/new-biomarker-for-early-parkinson-s-detection-shows-over-90-accuracy-in-clinical-trials 2025-04-28T13:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/purespring-s-ps-002-receives-ema-orphan-drug-designation-for-iga-nephropathy-treatment 2025-04-28T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/news/immvira-reports-favorable-safety-profile-for-oncolytic-virus-mvr-c5252-in-phase-i-glioma-trial 2025-04-28T13:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-pharmaceuticals-advances-novel-sublingual-semaglutide-formulation-to-challenge-injectable-glp-1-market 2025-04-28T13:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/pretomanid-price-drops-25-boosting-access-to-life-saving-tb-treatment-across-africa 2025-04-28T13:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-commits-2-billion-to-expand-us-manufacturing-and-r-d-capabilities 2025-04-28T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-adma-biologics-innovative-yield-enhancement-process-for-immune-globulin-production 2025-04-28T13:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/pci-pharma-services-to-acquire-ajinomoto-althea-expanding-us-fill-finish-capabilities 2025-04-28T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-unveils-promising-preclinical-data-for-stx-003-mrna-therapy-targeting-solid-tumors 2025-04-28T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-launches-first-tissue-test-with-comprehensive-multiomic-analysis-for-cancer-profiling 2025-04-28T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-reports-promising-results-for-zoldonrasib-in-kras-g12d-mutant-lung-cancer 2025-04-28T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/brain-navi-partners-with-first-securities-for-ipo-aims-to-accelerate-global-medtech-expansion 2025-04-28T10:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-blackfinbio-s-novel-gene-therapy-trial-for-rare-childhood-neurological-disease-spg47 2025-04-28T10:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/radspherin-r-shows-promising-18-month-results-in-ovarian-cancer-trial-with-90-recurrence-free-rate 2025-04-28T10:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/prilenia-and-ferrer-form-eur500-million-partnership-to-commercialize-pridopidine-for-huntington-s-disease-in-europe 2025-04-28T08:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/telix-pharmaceuticals-faces-fda-setback-for-brain-cancer-imaging-agent 2025-04-28T07:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/senti-bio-s-logic-gated-car-nk-cell-therapy-shows-promising-results-in-aml-clinical-trial 2025-04-28T07:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-presents-promising-preclinical-data-for-cdk2-molecular-glue-degrader-in-hr-positive-breast-cancer-at-aacr-2025 2025-04-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/total-telcom-subsidiary-secures-100000-plus-royalties-in-strategic-licensing-deal-for-heater-controllers 2025-04-28T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/elpis-biopharmaceuticals-advances-multi-mechanism-armored-car-t-platform-for-solid-tumors 2025-04-28T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/y-mabs-presents-preclinical-pharmacokinetics-data-for-cd38-sada-pretargeted-radioimmunotherapy-at-aacr-2025 2025-04-28T04:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-presents-promising-preclinical-data-on-novel-mesothelin-targeting-adc-at-aacr-2025 2025-04-28T04:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-biological-aging-linked-to-30-higher-dementia-risk-new-study-finds 2025-04-28T03:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/depression-rates-surge-60-over-past-decade-new-nchs-data-reveals 2025-04-28T03:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-announces-comprehensive-ban-on-petroleum-based-food-dyes-by-2026 2025-04-28T03:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-confirms-proteinuria-as-primary-endpoint-for-dimerix-s-dmx-200-phase-3-fsgs-trial 2025-04-28T01:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/fakeeh-care-inks-mou-with-fosun-pharma-to-develop-cell-gene-therapies 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-performs-first-easee-brain-implant-surgery-for-drug-resistant-epilepsy-at-newcastle-hospitals 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/liberty-gold-ceo-cal-everett-retires-after-eight-years-dr-jon-gilligan-named-new-president-and-ceo 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/national-lipid-association-advocates-for-universal-lipoprotein-a-testing-to-enhance-cardiovascular-risk-assessment 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-therapy-targeting-cav-1-protein-shows-promise-in-preserving-memory-function-in-alzheimer-s-disease 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-coverage-of-glp-1-obesity-drugs-could-add-47-7-billion-to-federal-spending-over-10-years 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/y-mabs-initiates-phase-1-trial-of-cd38-sada-radioimmunotherapy-for-relapsed-non-hodgkin-lymphoma 2025-04-27T22:37:20+00:00 hourly 0.9 https://trial.medpath.com/news/precede-biosciences-unveils-breakthrough-liquid-biopsy-platform-for-tumor-gene-expression-at-aacr-2025 2025-04-27T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-considers-accelerating-obesity-drug-launch-following-landmark-roche-partnership 2025-04-27T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/novel-off-the-shelf-car-nk-cell-therapy-shows-complete-remission-in-relapsed-aml-patients 2025-04-27T22:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/novel-topical-gel-successfully-treats-painful-skin-rash-from-colorectal-cancer-therapy 2025-04-27T22:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/abpro-and-celltrion-s-abp-102-ct-p72-shows-promise-as-best-in-class-her2-t-cell-engager 2025-04-27T19:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-groundbreaking-aveir-leadless-pacemaker-shows-promise-in-first-in-human-conduction-system-pacing-study 2025-04-27T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-alone-successfully-treats-multiple-cancer-types-with-mmrd-mutation-eliminating-need-for-surgery 2025-04-27T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/dostarlimab-shows-promise-in-eliminating-need-for-surgery-across-multiple-dmmr-cancer-types 2025-04-27T19:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-breakthrough-pembrolizumab-doubles-disease-free-survival-in-locally-advanced-head-and-neck-cancer 2025-04-27T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/springworks-anticipates-chmp-opinion-on-nirogacestat-for-desmoid-tumors-in-q2-2025 2025-04-27T16:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/uniphar-launches-10th-cell-and-gene-therapy-project-expanding-global-access-to-advanced-treatments 2025-04-27T13:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/zenflow-s-spring-system-shows-durable-three-year-benefits-for-bph-patients-in-landmark-study 2025-04-27T13:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-volt-pfa-system-shows-impressive-12-month-results-for-atrial-fibrillation-treatment 2025-04-27T10:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-shows-improved-survival-in-newly-diagnosed-glioblastoma-patients-with-high-immune-infiltration 2025-04-27T07:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-gras-status-to-bestzyme-s-melliatm-brazzein-advancing-zero-calorie-sweetener-market 2025-04-27T04:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-afferatm-pfa-technologies-show-promising-results-for-atrial-fibrillation-treatment 2025-04-27T02:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/lee-health-heart-institute-reaches-100-patient-milestone-in-global-leapps-stroke-prevention-trial 2025-04-27T01:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/structured-linezolid-dose-reduction-shows-promise-in-drug-resistant-tb-treatment 2025-04-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-first-indigenous-hpv-test-kits-for-cervical-cancer-screening 2025-04-26T22:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/lifitegrast-shows-long-term-safety-and-efficacy-for-dry-eye-disease-in-7-year-analysis 2025-04-26T22:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-trofinetide-as-first-ever-treatment-for-rett-syndrome-opening-new-era-for-rare-genetic-disorder 2025-04-26T22:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-tepezza-for-thyroid-eye-disease-first-targeted-treatment-in-eu 2025-04-26T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-hugo-robotic-surgery-system-meets-primary-endpoints-in-landmark-urologic-trial 2025-04-26T19:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/spyglass-pharma-s-iol-mounted-drug-delivery-platform-shows-promising-18-month-results-for-glaucoma-patients 2025-04-26T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-receives-positive-chmp-opinions-for-denosumab-biosimilars-in-europe 2025-04-26T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-secures-2-35-million-in-public-offering-to-advance-cancer-immunotherapy-trials 2025-04-26T08:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-to-present-groundbreaking-cancer-research-at-aacr-annual-meeting-2025 2025-04-26T07:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/keymed-biosciences-advances-novel-cdh17-targeted-adc-for-gastrointestinal-cancers-with-ind-approval-in-china 2025-04-26T04:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-updates-guidelines-to-recommend-dpyd-testing-before-fluoropyrimidine-chemotherapy 2025-04-26T03:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-age-specific-disease-burdens-in-pediatric-and-adolescent-atopic-dermatitis-patients 2025-04-26T03:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-ink-launches-triallens-ai-powered-analytics-dashboard-transforms-clinical-trial-data-management 2025-04-26T02:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-withdraws-eu-application-for-troriluzole-in-spinocerebellar-ataxia-rbc-remains-optimistic 2025-04-26T02:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medtronic-s-omniasecure-world-s-smallest-defibrillation-lead-for-cardiac-patients 2025-04-26T01:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-medtech-reports-promising-3-month-data-for-omnypulse-platform-in-atrial-fibrillation-treatment 2025-04-26T01:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/proposed-25-pharmaceutical-tariffs-could-increase-us-drug-costs-by-51-billion-annually 2025-04-25T23:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requests-additional-trial-for-novavax-covid-19-vaccine-before-full-approval 2025-04-25T22:40:26+00:00 hourly 0.9 https://trial.medpath.com/news/veracyte-expands-decipher-prostate-test-to-metastatic-cancer-patients-offering-new-treatment-guidance-tool 2025-04-25T22:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-precise-mrd-test-shows-promise-for-personalized-treatment-in-renal-cell-carcinoma 2025-04-25T22:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-researchers-present-breakthrough-cancer-therapies-at-aacr-2025 2025-04-25T22:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/aacr-annual-meeting-2025-to-bridge-gap-between-cancer-science-and-clinical-practice 2025-04-25T22:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/billiontoone-to-showcase-advanced-liquid-biopsy-innovations-at-aacr-2025 2025-04-25T20:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/uk-court-of-appeal-grants-astrazeneca-interim-injunction-against-glenmark-s-generic-dapagliflozin 2025-04-25T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/nimbus-therapeutics-initiates-first-in-human-trial-of-ndi-219216-for-msi-h-tumors-resistant-to-standard-therapies 2025-04-25T19:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-fl-501-shows-promise-in-reversing-cancer-cachexia-in-preclinical-studies 2025-04-25T19:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-announces-900-million-manufacturing-expansion-in-ohio-creating-350-new-jobs 2025-04-25T19:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-secures-fda-approval-for-novel-cancer-drug-while-partner-summit-therapeutics-faces-sharp-stock-decline 2025-04-25T19:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-researchers-present-breakthrough-cancer-studies-at-aacr-2025-annual-meeting 2025-04-25T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/smart-drug-delivery-systems-market-poised-for-17-growth-as-chronic-disease-management-evolves 2025-04-25T19:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-withdraws-eu-application-for-spinocerebellar-ataxia-drug-dazluma 2025-04-25T19:36:04+00:00 hourly 0.9 https://trial.medpath.com/news/emercell-receives-ema-approval-to-study-allogeneic-nk-cell-therapy-for-diffuse-large-b-cell-lymphoma 2025-04-25T19:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/ema-s-role-in-regulatory-reliance-for-post-approval-changes 2025-04-25T19:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/uk-court-of-appeal-grants-astrazeneca-injunction-against-glenmark-s-diabetes-generic 2025-04-25T19:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/suven-pharmaceuticals-and-cohance-lifesciences-merger-approved-creating-1-billion-cdmo-powerhouse 2025-04-25T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/olema-s-kat6-inhibitor-op-3136-shows-promising-anti-tumor-activity-across-multiple-cancer-types 2025-04-25T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/pneumonia-antibiotic-piperacillin-shows-promise-as-targeted-lyme-disease-treatment-at-100-fold-lower-doses 2025-04-25T18:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-limited-sets-new-benchmark-with-india-s-largest-diabetes-real-world-evidence-study 2025-04-25T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-s-cd47-inhibitor-combination-with-keytruda-fails-in-dual-phase-ii-trials 2025-04-25T17:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/catalym-s-visugromab-shows-promise-in-enhancing-antibody-drug-conjugate-efficacy-by-blocking-gdf-15 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdr-life-s-novel-t-cell-engagers-show-superior-potency-against-solid-tumors-in-preclinical-studies 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vivavision-s-vvn461-shows-promising-results-in-phase-2-trial-for-non-infectious-anterior-uveitis 2025-04-25T16:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-recommends-approval-of-oczyesa-for-acromegaly-treatment-in-the-eu 2025-04-25T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-sephience-receives-positive-chmp-opinion-for-phenylketonuria-treatment-across-all-age-groups 2025-04-25T16:35:57+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trial-launches-to-test-sipavibart-as-potential-long-covid-treatment 2025-04-25T16:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-restructures-abandons-autoimmune-program-to-focus-on-cancer-cell-therapies 2025-04-25T16:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/evorpacept-keytruda-combination-fails-to-meet-primary-endpoints-in-head-and-neck-cancer-trials 2025-04-25T16:35:39+00:00 hourly 0.9 https://trial.medpath.com/news/queen-elizabeth-hospital-leads-uk-recruitment-in-global-astrazeneca-heart-failure-trial 2025-04-25T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/clearb-therapeutics-to-present-promising-preclinical-data-on-hepatitis-b-therapeutic-vaccine-at-easl-2025 2025-04-25T16:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-showcases-extensive-clinical-evidence-for-transplant-monitoring-solutions-at-ishlt-2025 2025-04-25T13:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-reports-strong-2024-financial-results-with-first-commercial-revenues-from-iqirvo-r 2025-04-25T11:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-appoints-renee-aguiar-lucander-as-new-ceo-marking-new-growth-phase 2025-04-25T10:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/nordic-pharma-launches-authorized-generic-of-maxitrol-for-bacterial-eye-infections 2025-04-25T10:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/syncromune-to-present-phase-1-data-on-novel-sync-t-therapy-for-metastatic-prostate-cancer-at-asco-2025 2025-04-25T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-circa-scientific-s-pericrosstm-epicardial-access-kit-with-100-success-rate-in-clinical-trial 2025-04-25T04:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/allarity-therapeutics-unveils-novel-predictive-tool-for-daratumumab-response-in-multiple-myeloma-patients 2025-04-25T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-analysis-reveals-20-therapies-in-development-for-open-angle-glaucoma-treatment 2025-04-25T01:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/avidicure-launches-with-50m-to-develop-novel-multifunctional-antibody-platform-for-cancer 2025-04-25T01:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/bpgbio-s-bpm31510-demonstrates-breakthrough-blood-brain-barrier-penetration-for-mitochondrial-disease-treatment 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/briacell-therapeutics-completes-13-8-million-public-offering-to-advance-cancer-immunotherapy-pipeline 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cn-bio-and-pharmaron-partner-to-advance-organ-on-a-chip-technology-for-drug-development 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avvio-medical-to-present-novel-urological-device-trial-results-at-2025-aua-annual-meeting 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/grove-biopharma-secures-30m-funding-expands-to-new-r-d-facility-in-chicago-s-fulton-market 2025-04-24T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/circle-pharma-to-reveal-dual-mechanism-of-novel-cyclin-a-b-rxl-inhibitors-at-aacr-2025 2025-04-24T23:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/montana-pioneers-experimental-treatment-hub-with-new-legislation-expanding-right-to-try 2025-04-24T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/lumicera-and-costco-partner-to-expand-cost-plus-specialty-pharmacy-services-for-chronic-and-rare-conditions 2025-04-24T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/araceli-biosciences-secures-11-2m-seed-funding-to-accelerate-ai-powered-drug-discovery-imaging 2025-04-24T22:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/corwave-s-novel-lvad-shows-promising-results-in-6-month-preclinical-study-advancing-to-human-trials 2025-04-24T22:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-launches-4500-crore-qip-to-strengthen-balance-sheet-and-reduce-debt 2025-04-24T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-and-pfizer-form-strategic-alliance-to-advance-cancer-therapies-using-liquid-biopsy-technology 2025-04-24T20:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/topas-therapeutics-to-present-promising-phase-2a-data-for-novel-celiac-disease-treatment-at-ddw-2025 2025-04-24T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/mosaic-therapeutics-acquires-two-clinical-stage-oncology-programs-from-astex-to-develop-novel-combination-therapies 2025-04-24T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-seeks-fda-approval-for-novel-serotype-e-botulinum-neurotoxin-for-glabellar-lines 2025-04-24T19:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/amplifier-health-and-xeomics-partner-to-advance-voice-based-diagnostic-ai-with-750000-global-voice-samples 2025-04-24T19:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-s-plozasiran-for-familial-chylomicronemia-syndrome-fast-tracked-for-eu-approval 2025-04-24T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-submits-interoperable-insulin-pump-to-fda-advancing-abbott-partnership 2025-04-24T19:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-halts-balinatunfib-monotherapy-development-after-phase-ii-psoriasis-trial-miss 2025-04-24T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarcopenia-pipeline-shows-robust-growth-with-18-pharma-companies-developing-novel-therapies 2025-04-24T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytoagents-advances-phase-1b-2a-trial-of-cto1681-for-cytokine-release-syndrome-in-car-t-cell-therapy-patients 2025-04-24T17:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/dt-109-novel-glycine-based-compound-shows-dual-efficacy-against-atherosclerosis-and-mash 2025-04-24T17:33:21+00:00 hourly 0.9 https://trial.medpath.com/news/promising-alzheimer-s-vaccine-targeting-tau-protein-advances-toward-human-trials 2025-04-24T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-q3-2025-approval-dates-for-three-breakthrough-therapies-targeting-rare-diseases 2025-04-24T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/india-conducts-first-human-gene-therapy-trial-for-hemophilia-in-landmark-collaboration 2025-04-24T16:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/veraxa-biotech-and-voyager-acquisition-to-merge-creating-1-64b-nasdaq-listed-cancer-therapeutics-company 2025-04-24T16:37:23+00:00 hourly 0.9 https://trial.medpath.com/news/renibus-completes-enrollment-in-pivotal-phase-3-protect-trial-of-rbt-1-for-cardiac-surgery-complications 2025-04-24T16:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/entod-pharmaceuticals-receives-first-global-approval-for-0-05-atropine-eye-drops-to-combat-childhood-myopia 2025-04-24T16:37:20+00:00 hourly 0.9 https://trial.medpath.com/news/liverpool-researchers-trial-oral-treatment-for-deadly-leishmaniasis-disease 2025-04-24T16:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-s-antiviral-cdi-988-shows-potent-activity-against-emerging-norovirus-variants 2025-04-24T16:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/ireland-launches-magic-i-first-national-genomics-study-to-transform-childhood-cancer-care 2025-04-24T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-to-present-key-hepatitis-b-and-delta-clinical-data-at-easl-congress-2025 2025-04-24T16:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/seed-therapeutics-advances-dual-breakthrough-programs-in-targeted-protein-degradation-at-aacr-2025 2025-04-24T16:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/akoya-biosciences-launches-advanced-adc-breast-cancer-assay-for-precision-oncology 2025-04-24T16:35:03+00:00 hourly 0.9 https://trial.medpath.com/news/granite-bio-emerges-with-100m-funding-and-novel-immunology-pipeline-for-ibd-and-allergies 2025-04-24T16:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ferring-pharmaceuticals-new-manufacturing-facility-for-bladder-cancer-gene-therapy-adstiladrin 2025-04-24T16:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/inhalerx-secures-38-5-million-funding-to-advance-novel-inhaled-therapies-for-cancer-pain-and-panic-disorder 2025-04-24T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/novel-non-hormonal-male-contraceptive-adam-shows-two-year-efficacy-in-clinical-trials 2025-04-24T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/koelis-and-bot-image-partner-to-enhance-prostate-cancer-detection-with-ai-powered-fusion-biopsy-technology 2025-04-24T16:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/cell-therapy-advances-show-promise-for-hepatocellular-carcinoma-treatment 2025-04-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/varenicline-shows-promising-results-for-youth-vaping-cessation-in-landmark-trial 2025-04-24T14:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-s-farapulse-pfa-system-shows-promising-results-for-persistent-atrial-fibrillation-treatment 2025-04-24T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-baloxavir-significantly-reduces-household-influenza-transmission-in-global-phase-iii-trial 2025-04-24T13:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/promising-pipeline-for-mantle-cell-lymphoma-treatment-22-therapies-under-development-by-20-companies 2025-04-24T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/etiome-emerges-with-50m-to-target-disease-biomarkers-before-symptoms-appear 2025-04-24T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/summit-s-ivonescimab-shows-promise-in-phase-iii-trial-against-established-lung-cancer-therapies 2025-04-24T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-s-multi-antigen-covid-19-vaccine-shows-promising-results-in-immunocompromised-patients 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/medit-and-graphy-form-strategic-alliance-to-transform-digital-orthodontics-with-3d-printed-clear-aligners 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/hydrogel-coated-membranes-reduce-t-cell-exhaustion-in-car-t-manufacturing 2025-04-24T11:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-elafibranor-shows-promise-in-phase-ii-trial-for-primary-sclerosing-cholangitis 2025-04-24T10:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/cytovation-secures-6m-funding-to-advance-cy-101-cancer-therapy-into-phase-ii-trials 2025-04-24T10:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-and-moebius-medical-s-mm-ii-shows-promising-results-for-knee-osteoarthritis-in-phase-2b-trial 2025-04-24T10:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/lotte-biologics-launches-dedicated-adc-manufacturing-facility-with-first-client-contract 2025-04-24T10:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-and-oncodesign-services-partner-to-advance-radiopharmaceutical-research-with-abylinktm-technology 2025-04-24T10:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/turbine-unveils-first-ever-virtual-lab-platform-for-cell-simulations-in-drug-development 2025-04-24T10:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/archetype-therapeutics-to-present-ai-discovered-lung-cancer-drug-candidates-at-aacr-2025 2025-04-24T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/antengene-to-showcase-six-innovative-cancer-therapies-at-aacr-and-asco-2025 2025-04-24T07:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/selution-slr-drug-eluting-balloon-shows-exceptional-3-year-patency-rates-in-peripheral-artery-disease-trials 2025-04-24T06:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/sagemedic-s-3d-microtumor-assay-shows-promise-for-personalized-cancer-treatment-at-aacr-2025 2025-04-24T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharma-to-present-positive-phase-2-data-for-tirabrutinib-in-pcnsl-and-ono-4578-in-rectal-cancer-at-asco-2025 2025-04-24T04:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitor-selection-in-myelofibrosis-balancing-anemia-management-with-disease-control 2025-04-24T03:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-battles-fda-over-gastroparesis-drug-hearing-delays 2025-04-24T02:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/orphan-therapeutics-accelerator-pioneers-novel-funding-model-to-rescue-ultra-rare-disease-treatments 2025-04-24T02:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-biologics-to-present-breakthrough-clinical-data-for-ibi363-pd-1-il-2-bispecific-antibody-at-asco-2025 2025-04-24T01:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/grail-to-present-real-world-data-from-100000-galleri-multi-cancer-detection-tests-at-aacr-2025 2025-04-24T01:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytics-biotech-to-present-pelareorep-data-for-pancreatic-cancer-at-asco-2025 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-increased-kidney-and-liver-toxicity-with-pembrolizumab-chemotherapy-combination-in-lung-cancer 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-delgocitinib-cream-outperforms-alitretinoin-in-landmark-delta-force-trial-for-chronic-hand-eczema 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/itm-and-alpha-9-oncology-partner-to-supply-rare-actinium-225-for-advanced-cancer-therapies 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-secures-90-million-in-public-offering-to-advance-rare-disease-therapies 2025-04-23T23:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-follow-up-of-transform-trial-shows-sustained-benefits-of-liso-cel-car-t-cell-therapy-in-relapsed-lbcl 2025-04-23T22:37:30+00:00 hourly 0.9 https://trial.medpath.com/news/sickle-cell-disease-pipeline-shows-robust-growth-with-60-therapies-in-development-across-multiple-clinical-phases 2025-04-23T22:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/sakar-healthcare-secures-second-eu-marketing-authorization-for-colorectal-cancer-treatment 2025-04-23T22:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-to-showcase-breakthrough-cancer-therapies-at-asco-2025-with-over-60-presentations 2025-04-23T22:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-warns-of-serious-side-effects-from-unapproved-topical-finasteride-hair-loss-treatments 2025-04-23T22:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-tempus-ai-forge-200-million-oncology-ai-partnership-to-accelerate-cancer-drug-discovery 2025-04-23T20:36:57+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-s-cystic-fibrosis-drug-alyftrek-receives-chmp-recommendation-for-eu-approval 2025-04-23T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-ab8939-for-acute-myeloid-leukemia-treatment 2025-04-23T19:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-fermentalg-and-givaudan-s-acid-stable-natural-blue-food-colorant 2025-04-23T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/chimeric-therapeutics-raises-6-6-million-to-advance-novel-car-t-and-nk-cell-cancer-therapies 2025-04-23T19:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/nanostics-begins-clinical-utility-study-for-ai-powered-prostate-cancer-test 2025-04-23T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/biopoly-begins-fda-approved-clinical-trial-for-novel-knee-cartilage-implant 2025-04-23T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/new-research-reveals-how-vagus-nerve-encodes-immune-signals-during-inflammation 2025-04-23T19:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-apremilast-shows-dual-potential-for-alcohol-use-disorder-and-pain-management 2025-04-23T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-reports-positive-phase-3-results-for-ivonescimab-in-lung-cancer-building-on-recent-fda-approval-success 2025-04-23T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-astrazeneca-and-pathos-ai-form-200m-collaboration-to-build-oncology-foundation-model 2025-04-23T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-secures-landmark-victory-against-moderna-in-korean-mrna-patent-dispute 2025-04-23T16:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/baebies-secures-fda-breakthrough-designation-for-first-point-of-care-heparin-monitoring-test 2025-04-23T16:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/trustpoint-and-hexagon-secure-1-2m-navair-contract-to-develop-revolutionary-c-band-gnss-technology 2025-04-23T16:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-t1d-invests-2-8-million-to-establish-joint-cardiorenal-center-of-excellence-for-type-1-diabetes-research 2025-04-23T16:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-s-plasma-proteomics-research-reveals-key-mechanisms-of-immunotherapy-resistance-in-nsclc 2025-04-23T16:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-secures-patent-for-novel-methadone-based-opioid-use-disorder-treatment 2025-04-23T16:36:40+00:00 hourly 0.9 https://trial.medpath.com/news/cerevasc-s-eshunt-system-receives-fda-breakthrough-designation-for-pediatric-hydrocephalus-treatment 2025-04-23T16:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/tegoprazan-outperforms-standard-ppi-therapy-in-phase-3-gerd-trials 2025-04-23T16:36:36+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-and-tessellate-bio-form-eur500m-partnership-to-target-alt-positive-cancers 2025-04-23T16:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-phase-3-panova-3-trial-shows-promising-results-for-pancreatic-cancer-treatment 2025-04-23T16:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/peanut-allergy-treatment-market-poised-for-16-growth-as-new-therapies-enter-pipeline 2025-04-23T16:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-mursla-bio-s-evoliver-test-for-early-liver-cancer-detection 2025-04-23T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-unveils-advanced-cancer-genomic-profiling-tools-at-aacr-2025 2025-04-23T16:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/lakeshore-biopharma-launches-first-needle-free-rabies-vaccine-reconstitution-system-in-china 2025-04-23T16:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-partners-with-repertoire-immune-medicines-in-765m-deal-for-autoimmune-disease-drug-discovery 2025-04-23T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-appoints-utpal-singh-as-cso-to-advance-peptide-therapeutics-for-obesity 2025-04-23T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/sylvester-comprehensive-cancer-center-to-present-groundbreaking-research-at-asco-2025-annual-meeting 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardiff-oncology-secures-second-patent-for-onvansertib-in-bevacizumab-naive-mcrc-patients 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/merus-to-present-petosemtamab-combination-therapy-data-for-head-and-neck-cancer-at-2025-asco-meeting 2025-04-23T15:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/hawaii-advances-psychedelic-assisted-therapy-research-bill-with-4-million-funding-potential 2025-04-23T15:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-shows-promise-for-slowing-biological-aging-and-improving-cognition-in-hiv-patients 2025-04-23T14:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/cuban-drug-jusvinza-advances-through-phase-iii-trial-for-rheumatoid-arthritis-treatment 2025-04-23T11:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/remap-cap-trial-shows-hydrocortisone-reduces-mortality-in-severe-community-acquired-pneumonia 2025-04-23T11:00:14+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-reverses-course-on-company-split-appoints-henry-gosebruch-as-new-ceo 2025-04-23T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/parabilis-medicines-demonstrates-first-ever-degradation-of-erg-in-prostate-cancer-models 2025-04-23T09:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-da-1241-shows-enhanced-hepatoprotective-effects-in-mash-combination-therapy 2025-04-23T08:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/calidi-biotherapeutics-appoints-eric-poma-as-new-ceo-to-advance-novel-cancer-virotherapy-platform 2025-04-23T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-to-present-phase-1-data-on-novel-dll3-targeted-adc-for-small-cell-lung-cancer-at-asco-2025 2025-04-23T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/obi-pharma-s-novel-trop2-adc-obi-902-receives-fda-ind-clearance-for-phase-1-2-trial-using-proprietary-glycobi-r-technology 2025-04-23T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-avava-s-focal-point-technology-for-acne-scar-treatment-across-all-skin-types 2025-04-23T07:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/novita-s-fascin-inhibitor-np-g2-044-shows-promising-results-in-phase-2-trial-for-advanced-solid-tumors 2025-04-23T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mallinckrodt-to-present-five-clinical-studies-on-terlivaz-for-hepatorenal-syndrome-at-ddw-2025 2025-04-23T06:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/abtherx-partners-with-rondo-and-spice-biotechnologies-to-accelerate-bispecific-antibody-development-for-cancer-immunotherapy 2025-04-23T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pacbio-partners-with-davos-alzheimer-s-collaborative-on-groundbreaking-north-african-dementia-registry 2025-04-23T05:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/genscript-biotech-and-nsg-bio-form-strategic-partnership-to-accelerate-biotech-innovation-in-singapore 2025-04-23T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-monitoring-shows-promise-for-predicting-melanoma-recurrence-after-surgery 2025-04-23T02:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/arbutus-biopharma-to-present-promising-imdusiran-and-ab-101-data-for-chronic-hepatitis-b-at-easl-congress-2025 2025-04-23T02:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-partners-with-concertai-to-accelerate-precision-oncology-drug-development-using-ai 2025-04-23T02:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-s-rec-4881-shows-30-polyp-reduction-in-fap-patients-in-phase-1b-2-trial 2025-04-23T01:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/sonoma-pharmaceuticals-hypochlorous-acid-based-acne-products-gain-uk-regulatory-approval 2025-04-23T01:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-showcases-efanesoctocog-alfa-data-from-xtend-phase-3-program-at-wfh-2025-summit 2025-04-23T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-pfizer-lyme-disease-vaccine-shows-promise-with-strong-booster-response-in-phase-2-trial 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-olumiant-shows-promise-in-preserving-beta-cell-function-in-type-1-diabetes 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1cell-ai-launches-oncoincytes-revolutionary-multi-modal-cancer-diagnostic-panel-for-precision-oncology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/migraine-treatment-pipeline-shows-robust-activity-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-devices-receives-u-s-patent-for-hybrid-voice-and-gesture-control-technology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-and-element-biosciences-form-strategic-alliance-to-expand-ngs-technology-access-across-global-markets 2025-04-22T23:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-ceo-paul-stoffels-to-step-down-as-company-splits-into-two-entities 2025-04-22T23:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-cobenfy-fails-to-meet-primary-endpoint-as-adjunctive-schizophrenia-treatment-in-phase-3-arise-trial 2025-04-22T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/news/novonesis-invests-5-million-to-expand-biotechnology-operations-in-salem-virginia 2025-04-22T22:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/springworks-ogsiveo-expected-to-receive-positive-chmp-opinion-boosting-european-market-potential 2025-04-22T19:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ark-surgical-s-lapbox-power-first-dual-wall-system-for-both-manual-and-power-morcellation 2025-04-22T19:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/metro-international-biotech-initiates-phase-1a-trial-of-novel-nad-booster-mib-725-for-age-related-diseases 2025-04-22T19:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/elite-clinical-network-and-healthyu-clinics-form-strategic-partnership-to-transform-clinical-research-access 2025-04-22T19:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/axoft-s-ultrasoft-brain-computer-interface-shows-promising-results-in-first-human-trial 2025-04-22T17:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/halda-therapeutics-appoints-dr-eyal-attar-as-chief-medical-officer-to-advance-novel-riptac-cancer-platform 2025-04-22T17:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/smsbiotech-partners-with-u-s-army-to-develop-stem-cell-therapy-for-chemical-warfare-injuries 2025-04-22T16:40:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-luminopia-s-digital-therapeutic-approval-for-amblyopia-treatment-to-children-aged-8-12 2025-04-22T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/biostate-ai-and-weill-cornell-medicine-partner-to-develop-ai-driven-personalized-treatment-models-for-leukemia 2025-04-22T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/immune-checkpoint-inhibitors-equally-effective-in-older-and-younger-cancer-patients-despite-immune-phenotype-differences 2025-04-22T16:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-in-class-antibody-drug-conjugate-tgw101-for-advanced-solid-tumor-clinical-trial 2025-04-22T16:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/sirona-biochem-forms-strategic-partnership-with-promura-gmbh-secures-3m-investment-for-anti-aging-product-development 2025-04-22T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/eu-biosimilar-filings-opinions-and-approvals 2025-04-22T16:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/ocumetics-advances-revolutionary-accommodating-intraocular-lens-to-first-in-human-surgery-this-summer 2025-04-22T16:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-considers-international-reference-pricing-to-slash-u-s-drug-costs 2025-04-22T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/perfuze-completes-enrollment-in-pivotal-stroke-treatment-trial-strengthens-leadership-team 2025-04-22T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/roche-and-regeneron-announce-multi-billion-dollar-investments-in-us-manufacturing-amid-tariff-concerns 2025-04-22T16:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-licenses-first-in-class-antibody-targeting-activin-e-for-obesity-and-cardiometabolic-diseases 2025-04-22T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-brainchild-bio-s-car-t-cell-therapy-for-fatal-pediatric-brain-tumors 2025-04-22T16:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-orchestra-biomed-s-avim-therapy-for-hypertension 2025-04-22T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-expands-biologic-manufacturing-capacity-with-3-billion-fujifilm-partnership 2025-04-22T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/malaysia-strengthens-clinical-research-infrastructure-through-strategic-partnerships-and-record-breaking-trial-activity 2025-04-22T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/carthera-enrolls-100-patients-in-landmark-sonobird-trial-using-ultrasound-to-breach-blood-brain-barrier-in-glioblastoma 2025-04-22T16:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/neurovation-labs-secures-patent-for-novel-ptsd-biomarker-detection-technology 2025-04-22T15:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-microglia-a-revolutionary-approach-to-treating-alzheimer-s-disease 2025-04-22T13:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/design-therapeutics-to-present-phase-1-data-for-novel-fecd-eye-drop-treatment-at-ophthalmology-conference 2025-04-22T11:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/cellenkos-novel-off-the-shelf-treg-cell-therapy-demonstrates-promising-results-in-als-clinical-study 2025-04-22T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/lipum-s-sol-116-shows-promising-phase-i-results-for-rheumatoid-arthritis-treatment 2025-04-22T10:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/invivoscribe-s-labpmm-secures-new-york-state-approval-for-ultra-sensitive-flt3-itd-mrd-assay-in-aml 2025-04-22T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/1stbio-and-ligachembio-form-strategic-alliance-to-develop-next-generation-oncology-therapeutics 2025-04-22T10:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/enhertu-demonstrates-progression-free-survival-benefits-in-advanced-breast-cancer-trial 2025-04-22T10:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/vivasure-medical-secures-ce-mark-for-first-fully-absorbable-large-bore-vascular-closure-system 2025-04-22T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-s-shield-multi-cancer-detection-test-shows-strong-performance-across-10-cancer-types 2025-04-22T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ensem-therapeutics-ind-for-novel-pi3ka-inhibitor-etx-636-for-advanced-cancer-treatment 2025-04-22T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-to-present-promising-preclinical-data-on-protac-bcl6-degrader-arv-393-at-aacr-2025 2025-04-22T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-metabolite-hya-shows-promise-for-blood-sugar-management-in-type-1-diabetes 2025-04-22T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/personalis-to-present-new-data-on-next-personal-ctdna-test-for-early-cancer-detection-at-major-oncology-conferences 2025-04-22T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-optune-lua-receives-ce-mark-for-metastatic-non-small-cell-lung-cancer-treatment 2025-04-22T04:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/ernexa-therapeutics-to-present-promising-erna-101-data-for-ovarian-cancer-at-aacr-2025 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/minoryx-and-neuraxpharm-submit-new-marketing-authorization-application-for-leriglitazone-in-cerebral-adrenoleukodystrophy 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/surveil-dcb-shows-comparable-efficacy-to-in-pact-admiral-with-75-lower-paclitaxel-dose-in-transcend-trial 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transneural-therapeutics-unveils-novel-non-hallucinogenic-neuroplastogens-for-neuropsychiatric-disorders 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-at-ut-health-san-antonio-chemical-endocytic-strategy-could-transform-iv-drugs-into-oral-treatments 2025-04-21T23:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-neuronos-for-phelan-mcdermid-syndrome-treatment 2025-04-21T22:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/dual-targeted-car-t-cell-therapy-shows-100-response-rate-in-relapsed-refractory-mantle-cell-lymphoma 2025-04-21T19:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-cancer-drug-navitoclax-shows-promise-in-enhancing-tuberculosis-treatment 2025-04-21T19:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/vcu-massey-becomes-first-virginia-center-to-offer-robotic-hifu-for-prostate-cancer-treatment 2025-04-21T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/field-medical-secures-40-million-series-a-financing-to-advance-pulsed-field-ablation-for-ventricular-tachycardia 2025-04-21T16:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-study-confirms-hydroxyurea-s-safety-and-efficacy-in-pediatric-sickle-cell-disease 2025-04-21T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/titan-x-ai-platform-accelerates-development-of-novel-immunoregulatory-therapeutics-for-autoimmune-diseases 2025-04-21T16:40:19+00:00 hourly 0.9 https://trial.medpath.com/news/nadofaragene-firadenovec-shows-75-complete-response-rate-in-japanese-phase-3-trial-for-bcg-unresponsive-bladder-cancer 2025-04-21T16:40:14+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-24-of-difficult-to-control-type-2-diabetes-patients-have-hypercortisolism 2025-04-21T16:40:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-commissioner-makary-proposes-new-approval-pathway-for-rare-disease-drugs 2025-04-21T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-launches-generic-everolimus-in-canada-s-2-5b-oncology-market 2025-04-21T16:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/mural-oncology-cuts-90-of-workforce-following-failed-cancer-immunotherapy-trials 2025-04-21T16:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/vaccinex-s-pepinemab-shows-promise-in-turning-cold-tumors-hot-through-enhanced-immune-response 2025-04-21T16:38:53+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-develop-novel-rna-blood-test-for-cancer-detection-and-treatment-resistance-monitoring 2025-04-21T16:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/genesight-test-reduces-psychiatric-hospitalizations-in-major-depression-patients-study-shows 2025-04-21T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/icl-to-acquire-lavie-bio-strategic-move-to-advance-ai-driven-agricultural-biologicals 2025-04-21T14:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/grand-pharmaceutical-s-stc3141-shows-promise-in-phase-ii-sepsis-treatment-trial 2025-04-21T13:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-secures-30m-non-dilutive-loan-facility-to-advance-covid-19-antibody-pipeline 2025-04-21T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-ns-229-for-rare-vasculitis-condition 2025-04-21T13:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-enters-indian-oncology-market-with-venetoclax-for-blood-cancer-treatment 2025-04-21T13:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-groundbreaking-gene-therapy-for-dystrophic-epidermolysis-bullosa 2025-04-21T13:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/nanog-inhibition-shows-promising-results-in-glioblastoma-treatment-significantly-enhancing-temozolomide-efficacy 2025-04-21T11:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-dupilumab-for-chronic-spontaneous-urticaria-expanding-treatment-options 2025-04-21T11:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/vgenomics-and-meril-genomics-form-strategic-alliance-to-transform-precision-medicine-landscape-in-india 2025-04-21T10:36:36+00:00 hourly 0.9 https://trial.medpath.com/news/cgbio-s-novosis-putty-receives-fda-approval-for-pivotal-us-clinical-trials 2025-04-21T10:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/toolgen-files-patent-infringement-lawsuit-against-vertex-over-crispr-gene-therapy-casgevy 2025-04-21T10:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/inocras-and-d3b-launch-collaborative-research-to-decode-rare-sinonasal-cancer-genetics 2025-04-21T07:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/spring-allergy-management-expert-guidelines-for-comprehensive-patient-care 2025-04-21T04:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-hospital-and-kims-sunshine-partner-with-medtronic-to-launch-renal-denervation-therapy-centers-for-resistant-hypertension 2025-04-21T01:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/taipei-medical-university-and-msd-taiwan-forge-landmark-healthcare-innovation-partnership 2025-04-21T01:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/cemiplimab-shows-significant-survival-benefit-in-nsclc-patients-with-brain-metastases-and-high-pd-l1-expression 2025-04-20T22:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-advances-inhaled-antifungal-therapy-with-phase-iii-trial-approval-for-itraconazole-dry-powder 2025-04-20T19:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/senate-judiciary-committee-advances-six-bipartisan-bills-to-combat-high-drug-prices 2025-04-20T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-high-dose-radiotherapy-significantly-improves-survival-in-limited-stage-small-cell-lung-cancer 2025-04-20T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/unauthorized-drug-trials-exposed-at-ahmedabad-s-vs-hospital-over-500-patients-affected 2025-04-20T04:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/f2g-s-novel-antifungal-olorofim-shows-promise-despite-fda-setback-phase-2b-results-published-in-the-lancet 2025-04-19T20:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mini-protein-aky-1189-shows-promise-in-targeted-radiation-delivery-for-multiple-cancer-types 2025-04-19T19:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-measles-outbreak-reaches-800-cases-marking-largest-since-disease-elimination-in-2000 2025-04-19T19:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/uncomplicated-utis-impose-significant-economic-burden-on-healthcare-systems 2025-04-19T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/chime-biologics-and-polpharma-biologics-form-strategic-partnership-to-accelerate-global-biosimilar-development 2025-04-19T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/biologic-drug-costs-for-psoriasis-more-than-doubled-between-2007-2021-study-reveals 2025-04-19T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-restricts-industry-representatives-on-advisory-committees-to-restore-public-trust 2025-04-19T16:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-updates-camzyos-label-reduced-monitoring-requirements-and-expanded-patient-eligibility-for-hcm-treatment 2025-04-19T01:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/former-operation-warp-speed-leader-dr-matthew-hepburn-joins-panther-life-sciences-to-advance-microarray-patch-technology 2025-04-19T01:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/nusano-secures-major-supply-agreements-with-ratio-therapeutics-and-clarity-pharmaceuticals-to-address-critical-radioisotope-shortage 2025-04-19T01:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medtronic-s-simplera-sync-sensor-for-minimed-780g-system-expanding-cgm-options-for-diabetes-management 2025-04-19T01:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/compass-pathways-psilocybin-therapy-meets-primary-endpoint-in-largest-depression-trial 2025-04-19T01:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/bms-s-opdualag-shows-strong-early-performance-as-first-lag-3-checkpoint-inhibitor-for-melanoma 2025-04-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/kyowa-hakko-kirin-partners-with-inveniai-to-accelerate-drug-repurposing-using-ai-technology 2025-04-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nference-and-beigene-partner-on-ai-driven-research-to-advance-b-cell-cancer-treatment 2025-04-18T23:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/sparx-to-present-phase-1-data-on-novel-dual-checkpoint-inhibitor-spx-303-at-aacr-2025 2025-04-18T20:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-achieves-milestone-with-first-commercial-ppq-campaign-at-15000l-single-use-bioreactor-facility 2025-04-18T20:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/31-gene-expression-profile-test-safely-identifies-melanoma-patients-who-can-avoid-sentinel-lymph-node-biopsy 2025-04-18T19:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/notch1-mutations-predict-superior-immunotherapy-response-in-advanced-esophageal-cancer 2025-04-18T18:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-medtech-partners-with-braile-biomedica-to-expand-tavi-technology-across-europe-and-india 2025-04-18T18:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-genus-pic-s-gene-edited-prrs-resistant-pigs-in-landmark-decision 2025-04-18T18:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-disease-control-observed-in-nsclc-patients-after-immune-checkpoint-inhibitor-discontinuation 2025-04-18T18:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-alibaba-s-ai-for-early-pancreatic-cancer-detection 2025-04-18T18:46:32+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-pepaxti-effective-in-heavily-pretreated-multiple-myeloma-patients 2025-04-18T18:45:29+00:00 hourly 0.9 https://trial.medpath.com/news/early-discontinuation-of-adjuvant-immunotherapy-shows-no-negative-impact-on-melanoma-recurrence 2025-04-18T18:45:26+00:00 hourly 0.9 https://trial.medpath.com/news/nebraska-becomes-first-state-to-ban-soda-and-energy-drinks-from-snap-program 2025-04-18T18:43:45+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-cancels-800-million-in-lgbtq-health-research-funding 2025-04-18T18:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/women-with-autoimmune-diseases-face-50-higher-risk-of-heart-related-death-than-men 2025-04-18T18:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recalls-six-acne-products-after-testing-reveals-benzene-contamination-above-safety-limits 2025-04-18T18:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-measles-outbreak-intensifies-600-cases-reported-as-hhs-secretary-s-stance-on-vaccines-draws-criticism 2025-04-18T18:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/ob-gyn-workforce-shifts-following-abortion-bans-new-study-reveals-complex-migration-patterns 2025-04-18T18:30:28+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-reinstates-460-laid-off-employees-amid-ongoing-organizational-turmoil 2025-04-18T18:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-slashes-10000-hhs-jobs-amid-major-restructuring 2025-04-18T18:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-screening-rates-rebound-post-pandemic-but-cervical-cancer-prevention-lags-behind 2025-04-18T18:26:52+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-secures-dual-chmp-approvals-for-rare-liver-disease-treatments-following-regulatory-strategy-shift 2025-04-18T18:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-reverses-decision-to-end-free-covid-19-test-program 2025-04-18T18:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/evidence-review-finds-limited-effective-treatments-for-low-back-pain 2025-04-18T18:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-linked-to-elevated-risk-of-serious-eye-conditions-in-multiple-studies 2025-04-18T18:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/heart-disease-mortality-patterns-shift-as-acute-deaths-decline-while-chronic-conditions-rise 2025-04-18T18:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/heavy-cannabis-use-linked-to-triple-mortality-risk-and-rising-psychosis-cases-studies-find 2025-04-18T18:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/declining-childhood-vaccination-rates-raise-alarm-for-resurgence-of-preventable-diseases 2025-04-18T18:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-expands-drug-price-negotiations-to-include-15-high-cost-medications-including-ozempic-and-wegovy 2025-04-18T18:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-predicts-rapid-alzheimer-s-decline-using-insulin-resistance-marker 2025-04-18T18:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/risk-reducing-surgeries-significantly-improve-survival-in-brca-positive-breast-cancer-patients 2025-04-18T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-innovations-cbc-analysis-could-revolutionize-disease-detection-and-monitoring 2025-04-18T18:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/alcohol-and-substance-use-linked-to-rising-e-scooter-injuries-studies-show 2025-04-18T18:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/loneliness-epidemic-shifts-middle-aged-americans-more-isolated-than-seniors-new-research-reveals 2025-04-18T18:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/high-fiber-plant-based-diet-shows-promise-in-preventing-multiple-myeloma-progression-in-at-risk-patients 2025-04-18T18:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/expert-guidance-for-managing-holiday-activities-with-dementia-patients-practical-approaches-for-caregivers 2025-04-18T18:01:08+00:00 hourly 0.9 https://trial.medpath.com/news/radnet-to-acquire-icad-for-100-million-advancing-ai-powered-breast-cancer-detection 2025-04-18T18:00:51+00:00 hourly 0.9 https://trial.medpath.com/news/california-child-tests-positive-for-h5n1-bird-flu-without-known-animal-exposure 2025-04-18T17:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/medical-imaging-s-climate-impact-unnecessary-scans-contribute-significantly-to-carbon-emissions 2025-04-18T17:59:47+00:00 hourly 0.9 https://trial.medpath.com/news/rising-pancreatic-cancer-rates-in-young-adults-likely-due-to-improved-detection-not-increased-disease-burden 2025-04-18T17:59:43+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-diagnostic-tools-for-early-fatty-liver-disease-detection-ai-and-blood-tests-show-promise 2025-04-18T17:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/er-visits-for-psychedelics-linked-to-higher-mortality-and-schizophrenia-risk-studies-find 2025-04-18T17:58:15+00:00 hourly 0.9 https://trial.medpath.com/news/ultra-rapid-genetic-test-revolutionizes-brain-cancer-surgery-with-real-time-tumor-detection 2025-04-18T17:58:14+00:00 hourly 0.9 https://trial.medpath.com/news/studies-reveal-concerning-trends-in-prostate-cancer-treatment-overtreatment-rising-despite-serious-long-term-risks 2025-04-18T17:57:28+00:00 hourly 0.9 https://trial.medpath.com/news/first-u-s-case-of-more-virulent-mpox-strain-detected-in-california-traveler 2025-04-18T17:56:53+00:00 hourly 0.9 https://trial.medpath.com/news/mental-health-crisis-deepens-anxiety-and-depression-rates-surge-among-americans-particularly-youth 2025-04-18T17:56:50+00:00 hourly 0.9 https://trial.medpath.com/news/mindfulness-and-cbt-significantly-reduce-chronic-low-back-pain-and-opioid-use-in-landmark-clinical-trial 2025-04-18T17:55:38+00:00 hourly 0.9 https://trial.medpath.com/news/responsive-parenting-and-digital-support-significantly-reduce-childhood-obesity-risk-studies-show 2025-04-18T17:55:09+00:00 hourly 0.9 https://trial.medpath.com/news/autism-diagnoses-surge-175-in-the-u-s-over-past-decade-study-reveals 2025-04-18T17:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/hormonal-influences-on-asthma-risk-new-studies-reveal-gender-specific-patterns 2025-04-18T17:54:18+00:00 hourly 0.9 https://trial.medpath.com/news/weekend-warrior-exercise-pattern-offers-comparable-brain-health-benefits-to-regular-activity 2025-04-18T17:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-changes-linked-to-cognitive-decline-and-dementia-in-parkinson-s-disease 2025-04-18T17:53:21+00:00 hourly 0.9 https://trial.medpath.com/news/blue-cross-blue-shield-of-massachusetts-to-end-coverage-for-weight-loss-glp-1-drugs-in-2026 2025-04-18T12:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/australia-approves-ifinwil-eflornithine-for-high-risk-neuroblastoma-treatment 2025-04-18T11:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-qidp-status-to-venus-remedies-novel-antibiotic-vrp-034-for-bloodstream-infections 2025-04-18T08:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/velavigo-secures-440m-licensing-deal-for-first-in-class-bispecific-antibody-vbs-102 2025-04-18T07:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-vabysmo-becomes-first-approved-treatment-for-angioid-streaks-in-japan 2025-04-18T07:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-nurix-and-gilead-s-novel-irak4-degrader-gs-6791-nx-0479-for-inflammatory-conditions 2025-04-18T05:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-glasgow-and-mydna-partner-to-advance-pharmacogenomics-integration-in-nhs-healthcare 2025-04-18T05:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/precision-neuroscience-secures-fda-clearance-for-layer-7-cortical-interface-advancing-bci-technology 2025-04-18T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-acquires-fda-approved-generic-trametinib-anda-securing-180-day-market-exclusivity 2025-04-18T05:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/baypine-acquires-cenexel-clinical-research-aims-to-transform-clinical-trial-operations 2025-04-18T05:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-oral-glp-1-orforglipron-shows-promising-phase-3-results-for-weight-management 2025-04-18T03:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/promising-therapeutic-advances-for-rare-lymphomas-pi3k-inhibitors-ezh2-inhibitors-and-immunotherapy-show-clinical-potential 2025-04-18T03:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/endevica-bio-initiates-phase-2-trial-of-tcmcb07-for-cancer-cachexia-in-metastatic-colorectal-cancer-patients 2025-04-18T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/elraglusib-shows-promise-for-advanced-salivary-gland-carcinoma-in-upcoming-aacr-presentation 2025-04-18T02:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-initiates-phase-2-trial-of-sar441566-for-moderate-to-severe-ulcerative-colitis 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/balancing-efficacy-and-cost-sustainability-in-modern-cll-treatment-insights-from-dr-pierluigi-porcu 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-qure-ai-reach-5-million-ai-powered-chest-x-rays-for-lung-cancer-detection-across-20-countries 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/genedx-acquires-fabric-genomics-for-up-to-51-million-to-expand-global-genomic-diagnostics 2025-04-17T23:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/ai-in-healthcare-standardization-and-collaboration-key-to-future-success-experts-say 2025-04-17T22:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/who-member-states-reach-historic-draft-pandemic-agreement-after-three-years-of-negotiations 2025-04-17T22:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-advisory-panel-recommends-expanded-rsv-vaccination-for-adults-50-59-with-high-risk-conditions 2025-04-17T21:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-reports-67-revenue-growth-in-q1-2025-expands-product-portfolio 2025-04-17T20:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/brisk-walking-significantly-reduces-risk-of-heart-rhythm-disorders-new-study-finds 2025-04-17T20:41:28+00:00 hourly 0.9 https://trial.medpath.com/news/new-studies-reveal-menopause-often-begins-earlier-than-most-women-expect 2025-04-17T20:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/dr-mehmet-oz-confirmed-as-head-of-centers-for-medicare-medicaid-services 2025-04-17T20:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/modern-approaches-to-joint-replacement-recovery-faster-healing-less-pain 2025-04-17T20:37:59+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drug-use-surges-among-type-1-diabetes-patients-despite-safety-concerns 2025-04-17T20:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/smartwatch-innovation-new-heart-rate-to-step-ratio-emerges-as-superior-health-indicator 2025-04-17T20:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/trump-nominates-susan-monarez-as-permanent-cdc-director-after-weldon-withdrawal 2025-04-17T20:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/global-surge-in-early-onset-colorectal-cancer-demands-urgent-attention 2025-04-17T20:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/novel-screening-methods-show-promise-for-early-detection-of-cognitive-decline 2025-04-17T20:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/racial-disparities-in-ca-125-testing-may-delay-ovarian-cancer-treatment-for-black-and-native-american-women 2025-04-17T20:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-operation-stork-speed-to-modernize-infant-formula-safety-and-nutrition-standards 2025-04-17T20:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/measles-outbreak-spreads-across-multiple-states-with-two-fatalities-reported 2025-04-17T20:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-on-rising-nitrous-oxide-misuse-injuries-as-recreational-products-flood-market 2025-04-17T20:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-terminates-funding-for-geovax-s-next-generation-covid-19-vaccine-amid-ongoing-clinical-trials 2025-04-17T20:12:10+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-use-during-pregnancy-linked-to-tripled-risk-of-behavioral-disorders-in-children 2025-04-17T20:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-successfully-predicts-cognitive-decline-in-menopausal-women 2025-04-17T20:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/anti-inflammatory-drugs-and-infection-control-may-reduce-dementia-risk-studies-suggest 2025-04-17T20:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/utah-becomes-first-state-to-ban-fluoride-in-public-water-systems 2025-04-17T20:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/young-smokers-face-double-the-risk-of-unexplained-strokes-study-reveals 2025-04-17T20:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/environmental-pollutants-significantly-increase-childhood-asthma-risk-new-studies-reveal 2025-04-17T20:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/measles-outbreak-in-west-texas-escalates-to-58-cases-amid-low-vaccination-rates 2025-04-17T20:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/antidepressants-linked-to-increased-risk-of-sudden-cardiac-death-danish-study-reveals 2025-04-17T20:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/hormonal-contraceptives-and-hrt-linked-to-increased-cardiovascular-risks-in-women 2025-04-17T20:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/wildfire-smoke-exposure-linked-to-prolonged-cardiovascular-and-respiratory-health-risks 2025-04-17T20:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/roche-adjusts-tominersen-dosing-in-generation-hd2-trial-for-huntington-s-disease 2025-04-17T19:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/pregnancy-complications-linked-to-increased-heart-disease-risk-in-women-and-their-sisters 2025-04-17T19:47:14+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-orders-cdc-and-fda-to-restore-public-health-websites-removed-under-trump-administration 2025-04-17T19:47:06+00:00 hourly 0.9 https://trial.medpath.com/news/h5n1-bird-flu-may-spread-through-airborne-transmission-czech-study-reveals 2025-04-17T19:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/low-ldl-cholesterol-levels-associated-with-reduced-dementia-and-alzheimer-s-risk 2025-04-17T19:46:08+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-continues-to-pose-greater-health-threat-than-flu-and-rsv-study-finds 2025-04-17T19:45:55+00:00 hourly 0.9 https://trial.medpath.com/news/bariatric-surgery-in-adolescents-shows-superior-long-term-health-benefits-compared-to-adults 2025-04-17T19:45:19+00:00 hourly 0.9 https://trial.medpath.com/news/alarming-gap-in-dementia-diagnosis-awareness-reveals-healthcare-disparities 2025-04-17T19:43:16+00:00 hourly 0.9 https://trial.medpath.com/news/adhd-persists-in-adults-with-autism-at-rates-similar-to-childhood-study-finds 2025-04-17T19:43:15+00:00 hourly 0.9 https://trial.medpath.com/news/ketamine-use-surges-40-in-u-s-as-medical-authorities-call-for-stricter-controls 2025-04-17T19:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/menthol-cigarette-bans-drive-smokers-toward-cessation-therapies-rather-than-alternative-tobacco-products 2025-04-17T19:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/frequent-antibiotic-use-in-early-childhood-linked-to-higher-asthma-and-allergy-risk 2025-04-17T19:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-unveils-new-front-of-package-food-labels-to-combat-chronic-disease-epidemic 2025-04-17T19:41:27+00:00 hourly 0.9 https://trial.medpath.com/news/poor-sleep-quality-significantly-impacts-workplace-productivity-new-research-reveals 2025-04-17T19:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/exercise-significantly-reduces-cancer-mortality-risk-new-studies-confirm 2025-04-17T19:39:45+00:00 hourly 0.9 https://trial.medpath.com/news/hsv-1-infection-linked-to-80-increased-alzheimer-s-risk-in-large-scale-claims-analysis 2025-04-17T19:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/morning-coffee-consumption-linked-to-reduced-cardiovascular-death-risk-and-healthy-aging-in-women 2025-04-17T19:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/bilingualism-boosts-cognitive-function-in-children-with-autism-new-research-finds 2025-04-17T19:38:57+00:00 hourly 0.9 https://trial.medpath.com/news/early-physical-therapy-within-two-months-critical-for-concussion-recovery-clinical-trial-reveals 2025-04-17T19:38:03+00:00 hourly 0.9 https://trial.medpath.com/news/bird-flu-outbreak-linked-to-raw-pet-foods-prompts-multiple-recalls-across-us 2025-04-17T19:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/ai-advances-in-breast-cancer-detection-new-technologies-show-promise-for-earlier-diagnosis 2025-04-17T19:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/dance-therapy-shows-promising-results-for-parkinson-s-and-alzheimer-s-patients 2025-04-17T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/norovirus-outbreaks-on-cruise-ships-intensify-one-death-reported-amid-rising-cases 2025-04-17T19:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-confirms-concerning-mutations-in-first-severe-u-s-bird-flu-case 2025-04-17T19:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/team-sports-enhance-cognitive-development-and-academic-success-in-children-studies-show 2025-04-17T19:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/air-pollution-during-pregnancy-linked-to-severe-neonatal-health-risks-and-brain-development-issues 2025-04-17T19:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/omega-3-fatty-acids-show-promise-in-slowing-prostate-cancer-progression 2025-04-17T19:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-life-expectancy-rebounds-as-overdose-deaths-decline-for-first-time-in-a-decade 2025-04-17T19:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-historic-nicotine-reduction-in-tobacco-products-to-combat-addiction 2025-04-17T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/pediatric-flu-deaths-reach-highest-level-since-2009-as-vaccination-rates-decline 2025-04-17T19:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-effective-strategies-for-young-adults-quitting-vaping 2025-04-17T19:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/hpv-self-testing-proves-effective-for-cervical-cancer-screening-new-study-confirms 2025-04-17T19:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/malaria-suspected-in-deadly-congo-outbreak-as-laboratory-tests-show-positive-results 2025-04-17T19:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/dual-use-of-cigarettes-and-e-cigarettes-undermines-smoking-cessation-and-increases-health-risks 2025-04-17T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/physical-fitness-linked-to-better-cognitive-health-in-older-adults-studies-show 2025-04-17T19:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/salmonella-outbreak-linked-to-mexican-cucumbers-expands-to-100-cases-across-23-states 2025-04-17T19:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/socioeconomic-factors-and-parental-smoking-linked-to-worse-ms-outcomes-in-children 2025-04-17T19:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/preterm-birth-linked-to-lifelong-socioeconomic-and-health-disadvantages-studies-reveal 2025-04-17T19:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/wildfire-smoke-exposure-linked-to-increased-dementia-and-mental-health-risks-studies-find 2025-04-17T19:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/e-coli-contamination-prompts-massive-recall-of-167000-pounds-of-ground-beef 2025-04-17T19:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-launches-first-us-cell-therapy-collaboration-center-in-california 2025-04-17T19:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/alcohol-related-deaths-and-cancer-fatalities-surge-in-u-s-over-past-two-decades 2025-04-17T19:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/global-obesity-crisis-accelerating-80-of-americans-projected-to-be-overweight-or-obese-by-2050 2025-04-17T19:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/excessive-sedentary-time-linked-to-increased-cardiovascular-risk-even-in-active-individuals 2025-04-17T19:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-teen-s-critical-bird-flu-case-raises-alarm-as-h5n1-infections-spread 2025-04-17T19:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/adequate-sleep-significantly-reduces-hypertension-risk-in-adolescents-new-research-confirms 2025-04-17T19:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/obesity-related-cancer-deaths-more-than-triple-in-u-s-over-two-decades 2025-04-17T19:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/study-confirms-immediate-cpr-saves-lives-regardless-of-provider-training 2025-04-17T19:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-analysis-reveals-long-covid-affects-nearly-23-of-americans-higher-than-previous-estimates 2025-04-17T19:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/sleep-disruptions-emerge-as-critical-early-indicators-of-alzheimer-s-disease-risk 2025-04-17T19:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/maternal-vitamin-d-levels-during-early-pregnancy-significantly-impact-infant-health-outcomes 2025-04-17T19:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/whooping-cough-cases-surge-sixfold-in-the-u-s-reaching-highest-levels-since-2014 2025-04-17T19:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/h5n1-bird-flu-detected-in-u-s-pig-for-first-time-raising-transmission-concerns 2025-04-17T19:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/health-insurance-gaps-lead-to-later-cancer-diagnoses-among-black-and-hispanic-americans 2025-04-17T19:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/concussions-in-hockey-players-linked-to-doubled-risk-of-depression-and-tripled-risk-of-burnout 2025-04-17T19:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-medications-reshape-obesity-treatment-landscape-as-bariatric-surgeries-decline-25 2025-04-17T19:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-reports-second-missouri-bird-flu-case-without-animal-exposure-as-u-s-total-reaches-67 2025-04-17T19:02:21+00:00 hourly 0.9 https://trial.medpath.com/news/expanded-glp-1-drug-access-could-save-42000-lives-and-billions-in-healthcare-costs-annually 2025-04-17T19:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/infant-mortality-rises-in-states-with-abortion-bans-new-jama-studies-reveal 2025-04-17T19:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/election-related-stress-reaches-critical-levels-among-americans-apa-survey-reveals 2025-04-17T19:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/taylor-farms-recalls-onions-linked-to-deadly-e-coli-outbreak-in-mcdonald-s-quarter-pounders 2025-04-17T19:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/pfas-forever-chemicals-contaminate-drinking-water-for-75-95-million-americans-usgs-study-reveals 2025-04-17T19:00:59+00:00 hourly 0.9 https://trial.medpath.com/news/physical-activity-in-childhood-linked-to-better-mental-health-and-cognitive-function-in-adolescence 2025-04-17T19:00:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-bvi-medical-s-novel-laser-system-for-glaucoma-treatment 2025-04-17T18:37:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-25-first-time-generic-drugs-in-first-half-of-2025-expanding-access-to-critical-therapies 2025-04-17T18:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/probiogen-s-glymaxx-technology-powers-commercially-available-her2-biliary-cancer-treatment 2025-04-17T17:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-s-aramchol-shows-promising-results-in-enhancing-regorafenib-s-efficacy-against-gi-cancers 2025-04-17T17:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/sol-gel-and-mayne-pharma-announce-16-million-deal-for-epsolay-and-twyneo-rights-in-the-u-s 2025-04-17T17:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-executive-order-delays-medicare-drug-price-negotiations-sparking-industry-and-policy-debate 2025-04-17T15:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/ligand-s-pelthos-therapeutics-to-merge-with-channel-therapeutics-in-50m-deal-focused-on-molluscum-treatment 2025-04-17T15:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/channel-therapeutics-and-pelthos-therapeutics-merge-to-accelerate-zelsuvmi-launch-for-molluscum-contagiosum 2025-04-17T15:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/dasatinib-plus-car-t-cell-therapy-achieves-85-complete-molecular-remission-in-newly-diagnosed-ph-all 2025-04-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-secures-usfda-approvals-for-carbamazepine-and-amlodipine-atorvastatin-generics 2025-04-17T14:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/trodelvy-keytruda-combination-shows-promising-results-in-first-line-treatment-for-triple-negative-breast-cancer 2025-04-17T14:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/caliway-s-cbl-514-shows-promising-phase-2-results-for-dercum-s-disease-advancing-to-phase-2b-trial 2025-04-17T14:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/india-bans-35-unapproved-fixed-dose-combination-drugs-over-safety-concerns 2025-04-17T14:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/3d-pathology-technology-reclassifies-67-of-her2-null-breast-cancer-cases-as-her2-expressing 2025-04-17T12:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/diabetes-drug-metformin-shows-promise-in-preventing-acute-myeloid-leukemia 2025-04-17T11:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/solo-pace-receives-fda-clearance-for-novel-tavr-pacing-system-with-first-successful-human-procedures 2025-04-17T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-medline-s-reflex-hybrid-nitinol-implants-for-foot-and-ankle-surgery 2025-04-17T09:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-to-launch-generic-adderall-in-may-2025-amid-ongoing-shortage 2025-04-17T09:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/design-therapeutics-appoints-dr-chris-storgard-as-chief-medical-officer-to-advance-genetac-r-pipeline 2025-04-17T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-commits-1-3-billion-to-verve-therapeutics-cardiovascular-gene-therapy-platform 2025-04-17T06:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/porton-advanced-accelerates-development-of-innovative-cell-therapies-for-solid-tumors-with-key-partnerships 2025-04-17T06:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/iga-nephropathy-pipeline-shows-robust-growth-with-30-therapies-in-development 2025-04-17T06:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/sabin-launches-u-s-phase-2-trial-for-marburg-vaccine-amid-rising-global-outbreaks 2025-04-17T06:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/podo-therapeutics-advances-cancer-precision-medicine-with-novel-organoid-immune-cell-co-culture-platform 2025-04-17T06:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-secures-fda-approval-for-nubeqa-in-metastatic-prostate-cancer-targeting-eur3-billion-peak-sales 2025-04-17T05:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/yunu-secures-oversubscribed-funding-to-transform-clinical-trial-imaging-workflows 2025-04-17T05:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/sonrai-and-paige-partner-to-accelerate-precision-medicine-r-d-with-advanced-ai-capabilities 2025-04-17T02:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/global-regulatory-landscape-for-psoriasis-and-pompe-disease-treatments-evolving-in-2025 2025-04-17T02:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/sebiotic-r-probiotic-shows-96-efficacy-in-treating-drug-induced-constipation-in-clinical-trial 2025-04-17T01:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/biosidus-reports-positive-phase-iii-interim-results-for-agalsidase-beta-biosimilar-in-fabry-disease 2025-04-17T00:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/synaptixbio-selects-antisense-oligonucleotide-candidate-for-rare-disease-h-abc-clinical-trials 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-reports-record-growth-in-ycanth-r-dispensed-units-for-molluscum-contagiosum-treatment 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rehires-key-pharma-user-fee-negotiators-after-mass-layoffs-threaten-drug-review-process 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amt-medical-secures-25m-series-b-to-transform-coronary-bypass-surgery-with-minimally-invasive-technology 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mark-cuban-s-cost-plus-drug-company-partners-with-morris-dickson-to-address-injectable-medication-shortages 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-asset-purchase-deals-from-2019-2025 2025-04-16T23:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-therapeutics-advances-novel-cd19-t-cell-engager-to-phase-1-trial-for-rheumatoid-arthritis-in-europe 2025-04-16T23:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/tlx101-shows-promising-survival-benefits-in-recurrent-high-grade-glioma-patients 2025-04-16T21:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/ingenu-cro-launches-pioneering-clinical-trials-for-idiopathic-hypersomnia-and-narcolepsy 2025-04-16T20:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-s-opaganib-shows-promise-for-weight-loss-and-diabetes-potentially-disrupting-100b-market 2025-04-16T20:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-osilodrostat-isturisa-indication-for-broader-cushing-s-syndrome-treatment 2025-04-16T20:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-scilex-s-liquid-colchicine-for-pericarditis-treatment 2025-04-16T20:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-licenses-healthverity-s-real-world-data-to-transform-clinical-trial-design-and-analytics 2025-04-16T20:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/capricorn-scientific-and-florabio-partner-to-advance-animal-free-cell-culture-media-for-biotech-industry 2025-04-16T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/mural-therapeutics-discontinues-nemvaleukin-program-and-cuts-90-of-workforce-following-clinical-setback 2025-04-16T17:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/nanostics-secures-cpsa-accreditation-for-relocated-prostate-cancer-diagnostic-lab-in-edmonton 2025-04-16T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/accent-therapeutics-initiates-phase-i-ii-trial-of-novel-kif18a-inhibitor-for-advanced-solid-tumors 2025-04-16T17:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/cmg-pharmaceutical-secures-fda-approval-for-film-type-schizophrenia-treatment-mezofy 2025-04-16T17:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-launches-clinical-study-to-validate-smarttracktm-platform-for-accelerating-generic-inhaler-approvals 2025-04-16T17:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-partners-with-novartis-to-advance-genomics-research-and-precision-medicine 2025-04-16T17:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-valtoco-nasal-spray-for-seizure-clusters-in-children-ages-2-5 2025-04-16T17:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-completes-first-surgeries-with-ottava-robotic-system-in-clinical-trial 2025-04-16T17:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/clear-oasis-9-trial-colchicine-and-spironolactone-show-limited-benefits-after-myocardial-infarction 2025-04-16T17:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/oak-hill-bio-advances-rugonersen-for-angelman-syndrome-following-promising-phase-1-results-published-in-nature-medicine 2025-04-16T17:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-models-using-systemic-inflammation-markers-predict-neoadjuvant-chemotherapy-response-in-breast-cancer 2025-04-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-ceo-david-ricks-tops-pharma-executive-compensation-at-29-2-million-in-2024 2025-04-16T15:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/glycomine-secures-115m-series-c-funding-to-advance-novel-treatment-for-pmm2-cdg-rare-disease 2025-04-16T15:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/msd-and-cyprumed-forge-493-million-deal-to-advance-oral-peptide-therapeutics 2025-04-16T14:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/biovie-launches-sunrise-pd-trial-to-test-novel-anti-inflammatory-approach-for-early-parkinson-s-disease 2025-04-16T14:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-diagnostic-delays-for-minority-patients-with-generalized-myasthenia-gravis 2025-04-16T14:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-demonstrate-significant-renal-benefits-in-heart-failure-and-chronic-kidney-disease 2025-04-16T14:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/pgxai-launches-deneb-ai-model-to-revolutionize-drug-development-through-pharmacogenetics 2025-04-16T14:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/ritedose-doubles-vial-packaging-capacity-with-new-syntegon-line-to-support-ohtuvayre-copd-drug-production 2025-04-16T14:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/kras-inhibitors-market-set-to-exceed-2-billion-by-2030-with-next-generation-therapies-advancing 2025-04-16T14:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/cellino-and-karis-bio-partner-to-develop-first-autologous-ipsc-therapy-for-cardiovascular-disease 2025-04-16T13:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/octave-s-msda-test-transforms-ms-care-with-biomarker-driven-insights 2025-04-16T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ct-132-first-digital-therapeutic-for-episodic-migraine-prevention 2025-04-16T10:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/datchat-secures-european-patent-allowance-for-advanced-digital-privacy-technology 2025-04-16T08:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/thirtyfivebio-secures-bridge-financing-to-advance-novel-gpr35-inhibitor-for-ulcerative-colitis-treatment 2025-04-16T08:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/naya-therapeutics-regains-independence-to-advance-first-in-class-cancer-immunotherapies-with-2025-2026-clinical-milestones 2025-04-16T08:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/autonomix-medical-secures-european-patent-for-neuromodulation-technology-targeting-cancer-pain 2025-04-16T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-heart-failure-treatment-protocol-reduces-mortality-by-nearly-two-thirds-in-uk-hospitals 2025-04-16T08:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/luma-vision-s-verafeye-4d-cardiac-imaging-system-receives-fda-clearance 2025-04-16T08:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-breakthrough-tango-belt-device-that-reduces-hip-fractures-by-91-in-older-adults 2025-04-16T06:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ceribell-s-ai-algorithm-for-pediatric-seizure-detection-in-patients-as-young-as-one-year-old 2025-04-16T05:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-abeona-s-novel-cell-therapy-for-rare-skin-disease 2025-04-16T05:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/ziresovir-shows-breakthrough-efficacy-against-rsv-in-infants-under-6-months-with-long-term-benefits 2025-04-16T05:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-prescient-s-ptx-100-for-cutaneous-t-cell-lymphoma-treatment 2025-04-16T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-secures-settlement-with-regeneron-to-launch-aflibercept-biosimilar-in-us-by-2026 2025-04-16T05:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-validates-proenkephalin-a-119-159-as-superior-kidney-function-biomarker-in-critical-care 2025-04-16T04:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/tevogen-bio-partners-with-databricks-to-advance-ai-driven-immunotherapy-target-prediction-platform 2025-04-16T02:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/adar1-gene-identified-as-key-driver-of-lenalidomide-resistance-in-multiple-myeloma 2025-04-16T02:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/dm-clinical-research-partners-with-florida-sleep-specialists-to-advance-obesity-and-sleep-disorder-treatments 2025-04-16T02:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/scipher-medicine-and-kythera-labs-form-strategic-partnership-to-advance-precision-medicine-in-rheumatology 2025-04-16T01:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/turing-medical-appoints-kevin-king-as-ceo-to-advance-brain-mapping-technology-and-depression-treatment 2025-04-16T00:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/bluerock-therapeutics-reports-promising-18-month-data-from-phase-1-parkinson-s-cell-therapy-trial-in-nature-publication 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lenmeldy-4-25-million-gene-therapy-for-rare-childhood-disease-mld 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-s-m42-invests-in-juvenescence-to-advance-ai-driven-longevity-research 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-strengthens-competitive-edge-with-176-patent-global-portfolio 2025-04-15T23:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-and-cue-biopharma-partner-on-novel-b-cell-targeting-therapy-for-autoimmune-diseases 2025-04-15T23:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/repurposed-blood-pressure-drug-shows-promise-for-treating-inherited-retinal-diseases-with-sex-specific-benefits 2025-04-15T23:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-novel-dual-receptor-agonist-shows-promising-6-3-weight-loss-in-phase-1-obesity-trial 2025-04-15T23:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-to-launch-three-new-sample-preparation-instruments-by-2026-expanding-lab-automation-capabilities 2025-04-15T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-iltamiocel-for-post-cancer-treatment-dysphagia 2025-04-15T20:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-discovers-novel-blood-biomarkers-for-aramchol-expanding-therapeutic-potential-beyond-mash 2025-04-15T20:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-and-tempus-join-forces-to-advance-precision-medicine-through-ai-powered-genomics 2025-04-15T20:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-lyell-s-dual-targeting-car-t-cell-therapy-lyl314-for-relapsed-refractory-lbcl 2025-04-15T20:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/ssc-ild-market-projected-to-reach-750-million-by-2034-as-novel-therapies-enter-pipeline 2025-04-15T20:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-genetically-engineered-porcine-liver-system-to-treat-acute-on-chronic-liver-failure 2025-04-15T20:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-xellsmart-s-ipsc-derived-cell-therapies-for-parkinson-s-disease-and-als-clinical-trials 2025-04-15T18:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/neuphoria-advances-dual-clinical-programs-with-merck-partnership-milestone-and-phase-3-sad-trial-progress 2025-04-15T17:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-launches-multi-partner-initiative-to-advance-precision-medicine-and-genomic-healthcare 2025-04-15T17:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-acquires-tralesinidase-alfa-for-sanfilippo-syndrome-type-b-treatment-with-bla-submission-planned-for-2026 2025-04-15T17:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-strengthens-leadership-team-with-key-scientific-and-business-appointments 2025-04-15T17:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-terumo-neuro-s-first-in-class-dual-layer-micromesh-carotid-stent-system 2025-04-15T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/rege-nephro-acquires-tamibarotene-assets-from-syros-pharmaceuticals-for-adpkd-development 2025-04-15T17:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/mytomorrows-and-scout-clinical-launch-partnership-to-revolutionize-cross-border-clinical-trial-recruitment 2025-04-15T17:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-covid-19-vaccine-shows-fewer-side-effects-than-pfizer-biontech-in-shield-utah-study 2025-04-15T15:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-novo-nordisk-alert-consumers-to-counterfeit-ozempic-in-u-s-market 2025-04-15T15:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/uae-partnership-to-slash-car-t-cancer-therapy-costs-by-90-through-local-manufacturing 2025-04-15T14:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-sustained-release-flucytosine-enters-phase-ii-trials-for-cryptococcal-meningitis-amid-hiv-funding-crisis 2025-04-15T14:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/nimacimab-tirzepatide-combination-achieves-over-30-weight-loss-in-preclinical-obesity-study 2025-04-15T14:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/baylink-biosciences-to-present-novel-adc-platform-data-for-cancer-treatment-at-aacr-2025 2025-04-15T14:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-advances-car-nk-cell-therapy-to-overcome-clinical-bottlenecks 2025-04-15T14:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-reports-strong-q1-2025-darzalex-sales-of-3-24-billion-demonstrating-continued-market-dominance 2025-04-15T13:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/third-harmonic-bio-stockholders-approve-liquidation-plan-as-thb335-shows-85-tryptase-reduction-in-phase-1-trial 2025-04-15T12:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/norgine-expands-rare-disease-portfolio-with-strategic-acquisition-of-theravia 2025-04-15T11:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/coherus-biosciences-completes-558-4-million-udenyca-divestiture-to-intas-pivots-to-oncology-focus 2025-04-15T11:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-respiratory-pipeline-with-promising-amlitelimab-data-in-heterogeneous-inflammatory-asthma 2025-04-15T11:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-corxel-s-phase-ii-trial-for-oral-glp-1-receptor-agonist-cx11-in-obesity-treatment 2025-04-15T09:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/evommune-s-mrgprx2-antagonist-evo756-shows-promise-in-chronic-urticaria-trials 2025-04-15T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-advances-multi-antigen-covid-19-vaccine-and-expands-oncology-pipeline-despite-barda-setback 2025-04-15T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vascarta-launches-first-human-trial-of-transdermal-curcumin-therapy-for-sickle-cell-disease 2025-04-15T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/imperative-care-launches-first-randomized-trial-of-aspiration-thrombectomy-for-m2-stroke-occlusions 2025-04-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fluidform-bio-achieves-breakthrough-in-vascularized-tissue-engineering-for-diabetes-treatment 2025-04-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-cfo-and-coo-thad-huston-to-depart-as-company-advances-cell-therapy-transformation 2025-04-15T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/heparegenix-secures-eur21-5-million-to-advance-novel-liver-regeneration-therapy 2025-04-15T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-colorectal-cancer-drug-discovery-novel-nano-delivery-systems-and-precision-therapy-targets-identified 2025-04-15T01:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-lupus-nephritis-treatment-gsk-s-benlysta-autoinjector-for-pediatric-patients 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tvardi-therapeutics-completes-merger-with-cara-advances-stat3-inhibitor-programs-for-fibrosis-driven-diseases 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-raises-2025-sales-forecast-despite-400m-tariff-impact-following-intra-cellular-acquisition 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ripretinib-demonstrates-efficacy-as-neoadjuvant-therapy-for-gist-in-first-case-report 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chromatin-bioscience-and-astellas-partner-to-develop-cell-selective-synthetic-promoters-for-precision-gene-expression 2025-04-14T21:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/edwards-lifesciences-secures-first-ce-mark-for-transfemoral-mitral-valve-replacement-system 2025-04-14T21:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-partners-with-nhs-to-fast-track-promising-cancer-vaccine-trial 2025-04-14T21:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-conditional-approval-for-carmat-s-aeson-artificial-heart-second-cohort-study 2025-04-14T20:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/sohum-health-launches-nih-funded-clinical-trial-comparing-buprenorphine-formulations-for-rural-opioid-use-disorder-treatment 2025-04-14T18:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-secures-us-patent-for-masitinib-in-sickle-cell-disease-treatment-until-2040 2025-04-14T18:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/certara-launches-non-animal-navigator-solution-to-reduce-animal-testing-in-drug-development 2025-04-14T17:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-for-zoetis-canine-osteoarthritis-drug-librela-after-reports-of-serious-adverse-reactions 2025-04-14T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-biologics-poised-to-transform-30-2-billion-copd-market-by-2033 2025-04-14T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-partners-with-cgt-catapult-to-scale-cordstrom-manufacturing-for-rare-skin-disease-treatment 2025-04-14T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/ironwood-pharmaceuticals-faces-setback-as-fda-requires-additional-phase-3-trial-for-apraglutide 2025-04-14T17:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/reveal-genomics-and-ona-therapeutics-partner-to-advance-novel-adc-cancer-treatment-with-biomarker-strategy 2025-04-14T17:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/jama-oncology-study-confirms-oncotype-dx-test-effectiveness-across-all-racial-and-ethnic-groups 2025-04-14T17:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/pheast-therapeutics-initiates-phase-1-trial-of-novel-anti-cd24-macrophage-checkpoint-inhibitor-for-advanced-solid-tumors 2025-04-14T17:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/ironwood-pharmaceuticals-faces-setback-in-apraglutide-development-for-short-bowel-syndrome 2025-04-14T14:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-and-nhs-partner-to-accelerate-melanoma-vaccine-trial-recruitment 2025-04-14T14:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-biopharma-secures-3-million-in-funding-to-advance-clinical-trials-for-oncology-and-inflammatory-disease-treatments 2025-04-14T14:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/synact-pharma-launches-phase-ii-trial-of-resomelagon-for-dengue-treatment-in-brazil 2025-04-14T14:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bruno-vision-care-s-revolutionary-deseyne-contact-lenses-with-controlled-release-hydration-technology 2025-04-14T14:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/lobe-sciences-secures-6m-private-placement-for-novel-conjugated-psilocin-development-in-chronic-cluster-headache 2025-04-14T14:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-s-sys6041-and-syh2046-receive-fda-approval-for-clinical-trials 2025-04-14T14:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-cellenkos-ck0801-for-aplastic-anemia-treatment 2025-04-14T14:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/ainos-advances-veldona-oral-interferon-platform-with-dual-clinical-trial-approvals-for-rare-diseases 2025-04-14T14:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/once-weekly-insulin-icodec-combined-with-cgm-shows-promising-results-for-type-2-diabetes-management 2025-04-14T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/elix-and-prism-biolab-partner-to-revolutionize-drug-discovery-for-protein-protein-interaction-targets 2025-04-14T11:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bms-s-opdivo-yervoy-combination-for-first-line-treatment-of-advanced-liver-cancer 2025-04-14T11:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/dea-under-fire-for-seven-year-delay-in-medical-marijuana-research-application 2025-04-14T11:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-files-antitrust-lawsuit-against-amgen-to-unlock-access-to-etanercept-biosimilar-in-us-market 2025-04-14T07:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-leqselvi-advances-toward-launch-after-favorable-us-court-ruling 2025-04-14T07:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-ntap-for-sequana-medical-s-alfapump-system-boosting-medicare-access-for-cirrhosis-patients 2025-04-14T07:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-partners-with-heureka-labs-to-accelerate-sirt6-gene-therapy-development-using-ai 2025-04-14T07:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/acro-biomedical-secures-taiwanese-approval-for-novel-collagen-ophthalmic-matrix-to-address-global-corneal-transplant-shortage 2025-04-14T04:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-datopotamab-deruxtecan-for-previously-treated-egfr-mutated-nsclc 2025-04-14T02:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-expands-cancer-vaccine-launch-pad-to-include-promising-melanoma-treatment 2025-04-14T01:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-enhanced-total-neoadjuvant-therapy-shows-promise-for-locally-advanced-rectal-cancer 2025-04-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-emerges-as-most-effective-glp-1-agonist-for-diabetes-and-weight-loss-rapidly-overtaking-traditional-therapies 2025-04-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-therapeutics-bolsters-leadership-team-with-strategic-cfo-and-cmo-appointments-as-rna-editing-platform-advances-to-clinical-stage 2025-04-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-healthcare-secures-cdsco-approval-for-phase-iii-trials-of-two-copd-combination-therapies 2025-04-13T22:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/ugandan-scientist-secures-us-patent-for-revolutionary-cancer-treatment-using-crispr-technology 2025-04-13T22:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/lift-biosciences-appoints-dr-mark-exley-as-cso-to-advance-novel-neutrophil-therapy-into-clinical-trials 2025-04-13T22:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/oncodesign-services-appoints-dr-aidan-synnott-as-ceo-to-strengthen-drug-discovery-partnerships 2025-04-13T10:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-s-tanruprubart-shows-rapid-and-durable-improvements-in-guillain-barre-syndrome-phase-iii-trial 2025-04-12T23:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-successfully-completes-first-stem-cell-trial-for-knee-osteoarthritis-with-promising-results 2025-04-12T22:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-s-novel-antibiotic-zaynich-expected-to-receive-usfda-approval-in-2025 2025-04-12T22:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/plasma-based-mrd-analysis-shows-promise-for-predicting-recurrence-in-egfr-mutant-nsclc-following-osimertinib-treatment 2025-04-12T19:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/certolizumab-therapy-shows-breakthrough-results-for-high-risk-pregnancies-in-antiphospholipid-syndrome 2025-04-12T17:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-forms-elite-clinical-steering-committee-to-advance-novel-aml-therapeutic-program 2025-04-12T14:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-phases-out-animal-testing-requirement-for-monoclonal-antibodies-and-other-drugs 2025-04-12T13:40:38+00:00 hourly 0.9 https://trial.medpath.com/news/conduit-pharmaceuticals-files-novel-cocrystal-patent-for-vtama-extending-therapeutic-potential-beyond-2027 2025-04-12T13:40:36+00:00 hourly 0.9 https://trial.medpath.com/news/cms-policy-changes-create-new-reimbursement-challenges-for-505-b-2-oncology-drugs 2025-04-12T13:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/usc-study-confirms-safety-profile-of-covid-19-treatments-paxlovid-and-other-antivirals-show-minimal-serious-side-effects 2025-04-12T05:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-s-us-subsidiary-receives-11-fda-observations-following-inspection 2025-04-12T03:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/onesource-s-bengaluru-facility-secures-anvisa-gmp-approval-opening-doors-to-brazilian-market 2025-04-12T00:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ide-for-innoblative-s-sira-device-to-transform-breast-cancer-surgery 2025-04-11T23:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/first-canadian-patient-receives-personalized-mrna-therapy-for-bladder-cancer-in-muhc-trial 2025-04-11T23:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/coologics-launches-multi-center-trials-for-novel-cooling-device-to-treat-vaginal-yeast-infections 2025-04-11T23:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/cellistic-launches-echo-nk-platform-for-scalable-allogeneic-nk-cell-therapy-manufacturing 2025-04-11T21:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/solvonis-therapeutics-completes-acquisition-of-awakn-life-sciences-in-46-67-share-exchange-deal 2025-04-11T20:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/tavapadon-shows-promise-in-phase-3-trials-for-parkinson-s-disease-with-improved-motor-function-and-safety-profile 2025-04-11T17:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-simplified-dosing-regimen-for-acetadote-to-enhance-acetaminophen-overdose-treatment 2025-04-11T17:01:04+00:00 hourly 0.9 https://trial.medpath.com/news/vantage-biosciences-initiates-phase-2-trial-of-novel-oral-therapy-for-diabetic-retinopathy 2025-04-11T15:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-ide-approval-for-innoblative-s-novel-electrosurgical-device-for-breast-cancer-treatment 2025-04-11T14:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/titan-pharmaceuticals-secures-1-6-million-in-strategic-funding-through-two-convertible-preferred-stock-placements 2025-04-11T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biotech-to-present-promising-data-on-padeliporfin-vtp-for-utuc-and-prostate-cancer-at-aua-2025 2025-04-11T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-announces-shift-from-animal-testing-to-ai-models-boosting-recursion-pharmaceuticals-stock-20 2025-04-11T11:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-liver-directed-treatment-shows-promising-results-for-metastatic-uveal-melanoma 2025-04-11T11:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-receives-usfda-approval-for-generic-version-of-cancer-drug-abraxane 2025-04-11T09:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-approves-world-s-first-recombinant-anthrax-vaccine-barythrax 2025-04-11T09:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/phenylketonuria-pipeline-shows-robust-growth-with-25-therapies-in-development 2025-04-11T08:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-reports-positive-results-from-phase-iii-trial-of-new-plaque-psoriasis-treatment 2025-04-11T07:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-invisible-brain-cells-reverse-parkinson-s-symptoms-in-preclinical-study 2025-04-11T06:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/epsilogen-acquires-tigatx-to-create-leading-pan-isotype-cancer-antibody-company 2025-04-11T05:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/briapro-develops-novel-antibodies-targeting-b7-h3-for-multi-cancer-immunotherapy-applications 2025-04-11T05:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/turbett-surgical-secures-fda-510-k-clearance-for-enhanced-instrument-pod-systems-with-increased-capacity 2025-04-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fibrobiologics-opens-new-houston-laboratory-to-accelerate-fibroblast-based-therapeutics-development 2025-04-11T03:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-to-phase-out-animal-testing-requirement-for-monoclonal-antibodies-and-drugs 2025-04-11T02:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/arpa-h-awards-29-million-to-ginkgo-bioworks-consortium-for-revolutionary-wheat-based-pharmaceutical-manufacturing 2025-04-11T02:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-breast-cancer-drug-capivasertib-approved-for-nhs-use 2025-04-11T02:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-pre-filled-syringe-for-self-injection-of-efgartigimod-in-gmg-and-cidp-patients 2025-04-11T02:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-announces-23-billion-investment-to-expand-us-manufacturing-and-r-d-footprint 2025-04-11T02:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/hebrew-university-develops-revolutionary-xha-based-antibiotic-eyedrops-with-potential-for-human-applications 2025-04-11T01:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-stapler-for-single-port-robotic-surgery-with-da-vinci-sp-system 2025-04-11T01:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/inspire-trials-computerized-alerts-improve-antibiotic-selection-in-hospitalized-patients-by-up-to-35 2025-04-11T01:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/thriva-and-tasso-partner-to-revolutionize-blood-testing-for-needle-phobia-sufferers 2025-04-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-amlitelimab-shows-promising-results-in-atopic-dermatitis-trial-following-1-45bn-kymab-acquisition 2025-04-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-plans-to-phase-out-animal-testing-requirements-boosting-health-tech-stocks 2025-04-10T23:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/cefiderocol-shows-higher-efficacy-when-used-earlier-in-treatment-of-serious-gram-negative-infections 2025-04-10T23:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/omilancor-outperforms-anti-tl1a-therapies-in-ibd-treatment-shows-promise-for-severe-ulcerative-colitis 2025-04-10T22:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/daxor-submits-fda-510-k-for-next-generation-blood-volume-analyzer-with-enhanced-point-of-care-capabilities 2025-04-10T21:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-secures-75-million-in-equity-financing-to-advance-immunotherapy-pipeline 2025-04-10T21:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-vyepti-demonstrates-sustained-efficacy-in-migraine-prevention-at-aan-2025 2025-04-10T21:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/pridopidine-shows-promising-long-term-benefits-for-huntington-s-disease-patients-not-on-antidopaminergic-medications 2025-04-10T21:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/okeiro-secures-eur10-million-to-advance-ai-driven-precision-medicine-platform-for-transplantation-and-chronic-diseases 2025-04-10T20:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-launches-novel-sirt6-gene-therapy-program-for-eye-diseases 2025-04-10T20:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/myasthenia-gravis-market-set-to-reach-10-3-billion-by-2034-driven-by-seven-late-stage-pipeline-therapies 2025-04-10T20:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-s-pas-004-shows-strong-target-engagement-with-91-perk-inhibition-in-phase-1-cancer-trial 2025-04-10T20:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/pykus-therapeutics-completes-enrollment-for-novel-retinal-detachment-treatment-trial 2025-04-10T20:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/4basebio-secures-uk-regulatory-license-for-gmp-grade-synthetic-dna-production 2025-04-10T20:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/tempest-therapeutics-seeks-partner-for-phase-iii-liver-cancer-drug-amezalpat-amid-funding-challenges 2025-04-10T18:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/rivus-pharmaceuticals-strengthens-leadership-team-ahead-of-critical-phase-2b-mash-trial-results 2025-04-10T18:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/palatin-s-melanocortin-agonist-shows-promising-results-in-phase-2b-diabetic-kidney-disease-trial 2025-04-10T17:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/cytora-s-stem-cell-therapy-shows-promising-results-for-diabetic-foot-ulcers-in-phase-1-2a-trial 2025-04-10T17:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-hemophilia-b-gene-therapy-bbm-h901-shows-promising-results-in-single-dose-treatment 2025-04-10T17:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-s-raichur-unit-2-achieves-second-consecutive-zero-observation-fda-inspection 2025-04-10T17:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/brainstorm-advances-nurown-als-therapy-with-fda-aligned-phase-3b-trial-submission 2025-04-10T17:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-reports-promising-results-for-aramchol-meglumine-formulation-in-phase-1-bioavailability-study 2025-04-10T17:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/circular-rnas-emerge-as-promising-biomarkers-and-therapeutic-targets-in-colorectal-cancer-immunotherapy 2025-04-10T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hebe-biotechnology-appoints-dr-hannes-hentze-as-cdo-to-advance-novel-glp-1-weight-loss-therapy 2025-04-10T15:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/three-pharmaceutical-companies-advance-next-generation-covid-19-therapeutics-in-clinical-trials 2025-04-10T14:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/oculis-completes-enrollment-in-phase-3-diamond-trials-for-first-ever-topical-dme-treatment 2025-04-10T14:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/tempest-therapeutics-seeks-strategic-partner-for-promising-liver-cancer-drug-amezalpat-amid-funding-challenges 2025-04-10T14:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/ps10m-investment-in-ai-powered-robotic-labs-to-accelerate-infectious-disease-treatment-development 2025-04-10T14:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-phase-1-2-trial-of-ksq-004ex-crispr-engineered-til-therapy-for-advanced-solid-tumors 2025-04-10T14:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/theriva-biologics-presents-phase-1b-2a-safety-data-for-syn-004-in-hematopoietic-cell-transplant-recipients-at-escmid-global 2025-04-10T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/amacathera-partners-with-global-pharmaceutical-company-to-develop-single-injection-biologic-using-amacagel-platform 2025-04-10T11:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-court-ruling-clears-path-for-sun-pharma-s-alopecia-drug-leqselvi-launch 2025-04-10T11:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-biocon-biologics-bevacizumab-biosimilar-jobevne-for-multiple-cancer-indications 2025-04-10T11:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/aprocitentan-shows-significant-blood-pressure-and-proteinuria-reduction-in-black-patients-with-resistant-hypertension 2025-04-10T08:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/telo-genomics-multiple-myeloma-mrd-validation-data-accepted-for-asco-2025-annual-meeting 2025-04-10T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/recce-pharmaceuticals-secures-a-15-8-million-to-advance-phase-iii-trials-for-novel-anti-infectives 2025-04-10T08:03:07+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-of-80-therapies-advancing-in-psoriasis-treatment-landscape 2025-04-10T08:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/swinburne-university-and-tryptamine-therapeutics-launch-world-first-intravenous-psilocin-trial-for-binge-eating-disorder 2025-04-10T08:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-data-collaboration-key-to-advancing-cell-therapy-in-biopharma-industry 2025-04-10T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-researchers-discover-novel-approach-to-target-pancreatic-cancer-s-genetic-vulnerability 2025-04-10T05:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/northstrive-biosciences-advances-ai-powered-drug-discovery-for-obesity-and-cardiac-diseases 2025-04-10T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tonsil-removal-reduces-healthcare-needs-in-children-with-mild-sleep-disordered-breathing 2025-04-10T04:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/teen-substance-use-remains-at-historic-lows-in-2024-nih-survey-reveals 2025-04-10T04:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/bipartisan-bill-proposes-national-biotechnology-coordination-office-to-counter-china-s-growing-influence 2025-04-10T03:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/european-launch-sequencing-challenges-industry-experts-debate-solutions-at-reuters-pharma-europe-2025 2025-04-10T03:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/kandu-health-and-neurolutions-merge-to-create-comprehensive-stroke-recovery-platform-with-30m-financing 2025-04-10T02:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/acurion-launches-ai-powered-platform-to-revolutionize-precision-oncology-diagnostics 2025-04-10T02:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/liso-cel-combined-with-ibrutinib-shows-promise-for-relapsed-refractory-cll-and-richter-transformation 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/bluerock-therapeutics-partners-with-digital-health-companies-to-advance-parkinson-s-disease-clinical-trials 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/decade-long-uk-registry-reveals-key-insights-into-idiopathic-pulmonary-fibrosis-management-and-future-directions 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/dual-modal-approach-combining-oct-and-raman-spectroscopy-achieves-97-accuracy-in-skin-cancer-detection 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-unveils-life-sciences-strategy-to-strengthen-post-brexit-industry 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/adlai-nortye-to-showcase-novel-cancer-immunotherapy-and-ras-inhibitor-at-aacr-2025 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-oncology-market-projected-to-reach-3-51-billion-by-2035-with-14-7-cagr 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-secures-future-of-exparel-with-strategic-patent-settlement-agreement 2025-04-09T23:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/curateq-biologics-denosumab-biosimilar-meets-primary-endpoints-in-phase-1-study 2025-04-09T21:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/sunlight-trial-highlights-importance-of-sequential-therapies-in-refractory-colorectal-cancer 2025-04-09T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/sodium-channel-blockers-pipeline-surges-with-20-pharmaceutical-companies-developing-novel-therapies 2025-04-09T21:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/carmat-reports-strong-q1-2025-results-with-140-increase-in-aeson-r-artificial-heart-implants 2025-04-09T21:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-and-hikma-to-pay-195m-to-settle-antitrust-claims-over-narcolepsy-drug-xyrem 2025-04-09T20:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/merida-biosciences-launches-with-121m-to-target-disease-causing-antibodies-in-autoimmune-conditions 2025-04-09T20:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/addressing-the-unique-challenges-in-aya-non-hodgkin-lymphoma-care-expert-insights 2025-04-09T19:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/discgenics-cell-therapy-for-degenerative-disc-disease-receives-recognition-as-phase-iii-trial-approaches 2025-04-09T16:50:57+00:00 hourly 0.9 https://trial.medpath.com/news/nanorobots-for-drug-delivery-market-set-to-reach-1-73-billion-by-2030-transforming-precision-medicine 2025-04-09T16:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-zeiss-intrabeam-700-advanced-robotic-assisted-platform-for-intraoperative-radiotherapy 2025-04-09T16:50:22+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-and-enamine-launch-ai-powered-compound-libraries-to-accelerate-drug-discovery 2025-04-09T16:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-b-braun-s-piperacillin-and-tazobactam-in-duplex-drug-delivery-system 2025-04-09T16:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/probio-opens-128000-square-foot-gene-therapy-manufacturing-center-in-new-jersey 2025-04-09T16:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/infinitopes-secures-mhra-approval-for-phase-i-iia-trial-of-novel-cancer-vaccine-against-oesophageal-adenocarcinoma 2025-04-09T16:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/nexthera-initiates-phase-1-2a-trial-of-nt-101-eye-drops-for-wet-amd-potentially-eliminating-need-for-injections 2025-04-09T16:49:34+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-to-present-new-clinical-data-on-permeaderm-for-burn-and-wound-management-at-aba-2025 2025-04-09T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/sinomab-s-sm17-shows-breakthrough-results-in-phase-1b-trial-for-atopic-dermatitis 2025-04-09T14:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/longhorn-vaccines-advances-universal-flu-vaccine-with-broad-cross-species-protection 2025-04-09T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/cepheid-and-oxford-nanopore-partner-to-revolutionize-infectious-disease-sequencing-workflows 2025-04-09T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/orthopediatrics-launches-fda-cleared-verteglide-system-for-early-onset-scoliosis-treatment 2025-04-09T10:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/pridopidine-shows-promise-for-als-subgroups-in-healey-platform-trial 2025-04-09T10:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-enrolled-in-nih-funded-expanded-access-program-for-mn-166-in-advanced-als 2025-04-09T10:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-and-limmatech-advance-pioneering-shigella-vaccine-into-phase-2-trials 2025-04-09T08:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/cdmo-market-report-key-regulatory-approvals-and-clinical-advances-in-march-april-2025 2025-04-09T08:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-first-monkeypox-vaccine-enters-phase-i-clinical-trials-with-diverse-volunteer-cohort 2025-04-09T08:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-invests-1-09-billion-to-expand-glp-1-production-capacity-in-brazil 2025-04-09T07:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/kymera-therapeutics-appoints-noah-goodman-as-chief-business-officer-to-advance-protein-degradation-platform 2025-04-09T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/phenomix-sciences-launches-clinical-trial-to-predict-patient-response-to-glp-1-obesity-treatments 2025-04-09T05:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/2025-pharmaceutical-pipeline-major-patent-expirations-set-to-transform-drug-market-with-generics-and-biosimilars 2025-04-09T05:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/scientist-com-launches-clinical-labs-navigator-to-streamline-clinical-trial-management 2025-04-09T03:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-camizestrant-shows-56-reduction-in-breast-cancer-progression-risk-using-blood-test-guided-treatment 2025-04-09T03:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/orviglance-shows-superior-liver-lesion-detection-in-phase-ii-study-published-in-investigative-radiology 2025-04-09T02:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-cardiovia-s-viaone-system-for-safer-access-to-heart-surface-transforming-cardiac-interventions 2025-04-09T00:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-advances-world-s-first-pd-l1-adc-to-phase-2-trial-for-advanced-nsclc-treatment 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-clinical-trial-designs-gain-momentum-as-industry-embraces-efficiency-and-innovation 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-safety-analysis-reveals-distinct-adverse-event-profiles-across-anti-her2-drug-classes-in-breast-cancer-treatment 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vaxess-demonstrates-needle-free-glp-1-patch-achieves-comparable-bioavailability-to-injections 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-genetic-test-prostox-predicts-urinary-side-effects-from-prostate-cancer-radiation-therapy 2025-04-08T23:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/lifemine-therapeutics-initiates-first-in-human-trial-of-novel-calcineurin-inhibitor-life-001 2025-04-08T23:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-drug-compound-prevents-long-covid-symptoms-in-mice-offering-hope-for-first-treatment 2025-04-08T23:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-of-55-therapies-advancing-toward-potential-functional-cure-for-chronic-hepatitis-b 2025-04-08T22:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/international-psycho-oncology-society-establishes-first-world-psycho-oncology-day-to-advance-integrated-cancer-care 2025-04-08T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionova-scientific-partners-with-bionique-testing-laboratories-for-mycoplasma-testing-in-biologics-manufacturing 2025-04-08T21:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-workforce-cuts-lead-to-historic-drop-in-medical-device-approvals 2025-04-08T20:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-theratechnologies-egrifta-sv-prior-approval-supplement-and-alpha-tau-s-trial-for-recurrent-glioblastoma 2025-04-08T20:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/lipella-completes-enrollment-in-phase-iia-trial-for-novel-oral-lichen-planus-treatment 2025-04-08T20:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/als-drug-nu-9-shows-promising-results-for-alzheimer-s-disease-in-animal-study 2025-04-08T20:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/hospital-based-addiction-consultation-significantly-improves-oud-treatment-outcomes-study-shows 2025-04-08T20:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-withdraws-sickle-cell-drug-oxbryta-globally-following-safety-concerns 2025-04-08T18:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-settles-exparel-patent-litigation-with-fresenius-kabi-securing-market-exclusivity-until-2030 2025-04-08T17:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/toripalimab-induction-therapy-reduces-disease-progression-risk-by-74-in-bulky-stage-iii-nsclc 2025-04-08T16:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/bonyf-advances-novel-alginate-organic-denture-fixative-to-phase-3-clinical-development 2025-04-08T16:41:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-agitated-solutions-novel-cardiac-contrast-agent-advancing-to-phase-3-trials 2025-04-08T16:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-comanche-biopharma-s-cbp-4888-for-preeclampsia-treatment 2025-04-08T16:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/algernon-pharmaceuticals-secures-european-patent-for-repirinast-in-kidney-disease-treatment 2025-04-08T16:40:38+00:00 hourly 0.9 https://trial.medpath.com/news/japan-grants-first-orphan-drug-designation-for-myotonic-dystrophy-type-1-to-avidity-s-del-desiran 2025-04-08T16:40:37+00:00 hourly 0.9 https://trial.medpath.com/news/cosmos-health-expands-global-footprint-with-300000-sky-premium-life-launch-in-albania 2025-04-08T16:39:17+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-doses-first-patient-in-phase-1-trial-of-rec-3565-for-relapsed-b-cell-lymphomas 2025-04-08T16:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/science-37-achieves-second-fda-inspection-success-as-top-enroller-in-phase-3-asthma-trial 2025-04-08T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/engine-biosciences-and-eddc-form-strategic-partnership-to-develop-precision-cancer-therapies 2025-04-08T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-cbd-extract-may-reduce-autism-symptoms-in-children-and-adolescents 2025-04-08T14:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/novel-cytokine-factory-implant-shows-promise-against-hard-to-treat-cancers 2025-04-08T13:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-reports-strong-survival-benefit-in-phase-2-trial-of-bv100-for-carbapenem-resistant-acinetobacter-infections 2025-04-08T13:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-receives-1-million-milestone-as-takeda-advances-anti-cd83-antibody-mezagitamab-to-phase-3-for-itp 2025-04-08T13:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-moderna-s-combination-flu-covid-vaccine-amid-increased-regulatory-scrutiny 2025-04-08T13:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/cerevance-s-cvn293-shows-promising-safety-profile-and-brain-penetration-in-phase-1-trial-for-neurodegenerative-diseases 2025-04-08T11:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/ingenix-secures-eur9m-seed-funding-to-revolutionize-clinical-trials-with-ai-simulation 2025-04-08T10:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/cytotronics-unveils-neural-application-for-pixel-platform-revolutionizing-drug-discovery-for-neurological-diseases 2025-04-08T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-october-2025-pdufa-date-for-xspray-pharma-s-resubmitted-dasynoc-application 2025-04-08T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/realta-to-present-phase-2-clinical-data-on-novel-anti-inflammatory-therapy-for-newborn-brain-injury-at-pas-2025 2025-04-08T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/alzinova-secures-funding-for-phase-ii-alzheimer-s-drug-trial-preparations 2025-04-08T07:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/precision-for-medicine-and-sophia-genetics-form-strategic-partnership-to-revolutionize-clinical-trials-with-ai-driven-genomic-analysis 2025-04-08T07:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/diabetes-pipeline-shows-robust-growth-with-200-companies-developing-novel-therapies 2025-04-08T07:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/enanta-pharmaceuticals-to-present-promising-rsv-antiviral-data-at-major-european-medical-conferences 2025-04-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ampreloxetine-shows-promise-for-neurogenic-orthostatic-hypotension-in-msa-patients-without-worsening-supine-hypertension 2025-04-08T04:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/uk-invests-ps600-million-in-health-data-research-service-to-accelerate-clinical-trials 2025-04-08T02:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-warns-us-price-negotiations-will-impede-research-as-three-glp-1-drugs-face-scrutiny 2025-04-08T02:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/minnesota-developed-synerfuse-implant-for-chronic-back-pain-advances-toward-fda-approval 2025-04-08T01:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/uk-mhra-approves-trofolastat-first-psma-targeting-agent-for-prostate-cancer-imaging 2025-04-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-chimeric-autoantibody-receptor-t-cells-show-promise-for-treating-graves-disease 2025-04-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acrivon-therapeutics-appoints-renowned-oncologist-dr-mansoor-raza-mirza-as-chief-medical-officer-to-lead-clinical-development 2025-04-07T22:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/ai-discovered-drug-rentosertib-shows-promising-phase-iia-results-for-idiopathic-pulmonary-fibrosis 2025-04-07T22:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/taurx-s-lmtx-shows-promising-results-for-alzheimer-s-treatment-with-potential-to-become-first-oral-disease-modifying-therapy 2025-04-07T20:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-imcivree-shows-significant-weight-loss-in-phase-iii-hypothalamic-obesity-trial 2025-04-07T20:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-expands-global-cell-therapy-network-with-new-yokohama-facility-and-advanced-single-use-bioreactor-technology 2025-04-07T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/reunion-neuroscience-to-launch-rekindle-phase-2-trial-for-adjustment-disorder-in-cancer-patients-using-psychedelic-therapy 2025-04-07T16:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-s-crexont-shows-significant-sleep-quality-improvements-in-parkinson-s-disease-patients 2025-04-07T16:43:20+00:00 hourly 0.9 https://trial.medpath.com/news/nih-breakthrough-personalized-immunotherapy-shows-promise-against-gastrointestinal-cancers 2025-04-07T16:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-icu-medical-s-precision-iv-pumps-expanding-infusion-therapy-capabilities 2025-04-07T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-fast-tracks-sildenafil-cream-launch-with-dual-market-strategy-for-women-s-health 2025-04-07T16:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-avenacy-s-propofol-injectable-emulsion-as-generic-alternative-to-diprivan 2025-04-07T16:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/nordic-pharma-s-canalicular-gel-lacrifill-receives-ce-mark-for-dry-eye-disease-treatment 2025-04-07T16:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-s-imcivree-shows-significant-weight-loss-in-patients-with-hypothalamic-obesity 2025-04-07T16:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-transcriptomics-reveals-new-therapeutic-targets-for-head-and-neck-cancer-immunotherapy 2025-04-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ipl344-shows-promising-results-in-slowing-als-progression-in-phase-2a-trial 2025-04-07T14:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/adhd-medications-show-minimal-cardiovascular-effects-in-comprehensive-analysis 2025-04-07T14:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/lexeo-therapeutics-partners-with-investors-to-launch-40m-rna-cardiac-therapeutics-spinout 2025-04-07T14:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-teva-s-application-for-ajovy-in-pediatric-migraine-prevention-potentially-first-cgrp-antagonist-for-children 2025-04-07T14:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-secures-168-million-in-funding-to-advance-precision-medicine-platform 2025-04-07T13:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/curevac-advances-novel-mrna-immunotherapy-for-squamous-non-small-cell-lung-cancer-with-fda-ind-clearance 2025-04-07T13:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/erbc-and-menarini-biotech-form-strategic-alliance-to-accelerate-biopharmaceutical-development 2025-04-07T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-leadership-shuffle-continues-as-industry-navigates-transformation-in-q2-2025 2025-04-07T10:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/first-real-world-data-for-leqembi-reveals-implementation-challenges-in-alzheimer-s-treatment 2025-04-07T09:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-expands-neurodegenerative-disease-portfolio-with-2-5b-abl-bio-partnership 2025-04-07T08:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-launches-fexuclue-in-india-a-novel-treatment-for-erosive-esophagitis 2025-04-07T08:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-international-s-blood-test-achieves-91-4-accuracy-in-detecting-oesophageal-cancer 2025-04-07T07:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/neurelis-to-present-new-data-on-diazepam-nasal-spray-for-seizure-management-at-aan-annual-meeting 2025-04-07T05:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/specialty-pharmacists-drive-significant-improvements-in-non-ms-neurology-care-study-shows 2025-04-07T03:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-abl-bio-partner-on-ps2-billion-deal-to-overcome-blood-brain-barrier-in-neurodegenerative-disease-treatment 2025-04-07T02:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/nih-launches-first-clinical-trial-of-moderna-s-mrna-vaccine-against-deadly-nipah-virus 2025-04-07T01:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-insomnia-drug-suvorexant-shows-promise-in-reducing-alzheimer-s-related-proteins 2025-04-07T01:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/luye-pharma-launches-erzofri-single-dose-initiation-long-acting-injectable-for-schizophrenia-treatment 2025-04-06T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/china-advances-rice-derived-human-serum-albumin-to-new-drug-approval-stage 2025-04-06T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/once-nightly-sodium-oxybate-shows-safety-profile-in-narcolepsy-patients-with-sleep-apnea-concerns 2025-04-06T10:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/climate-change-and-neurological-health-expert-highlights-critical-connections-and-action-steps 2025-04-06T03:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapies-show-promise-for-chronic-spontaneous-urticaria-with-complete-response-rates-exceeding-30 2025-04-06T02:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/gene-editing-breakthrough-david-liu-s-base-and-prime-editing-technologies-transform-treatment-of-genetic-diseases 2025-04-06T01:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-scientist-dr-daniel-drucker-wins-breakthrough-prize-for-glp-1-hormone-discovery-behind-ozempic-and-mounjaro 2025-04-06T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/epilepsy-drug-ezogabine-shows-promise-as-novel-depression-treatment-by-targeting-brain-potassium-channels 2025-04-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/arizona-advances-bill-for-10m-ibogaine-clinical-trials-to-treat-ptsd-and-neurological-disorders 2025-04-05T23:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/incog-biopharma-services-announces-major-facility-and-capacity-expansion-for-2025 2025-04-05T22:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/bioskryb-genomics-forms-strategic-partnerships-to-revolutionize-single-cell-multi-omics-analysis 2025-04-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aptevo-therapeutics-secures-2-1-million-in-financing-to-advance-immune-oncology-pipeline 2025-04-05T17:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-gene-therapies-evolving-beyond-viral-vectors-towards-more-affordable-sustainable-solutions 2025-04-05T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-no-benefit-in-pausing-btk-inhibitors-during-covid-19-vaccination-for-cll-patients 2025-04-05T14:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/statins-show-promise-in-slowing-alzheimer-s-cognitive-decline-large-scale-studies-suggest 2025-04-05T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-questions-roche-on-high-pricing-of-sma-drug-risdiplam-in-india 2025-04-05T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-aurobindo-pharma-s-dyrupeg-new-pegfilgrastim-biosimilar-for-chemotherapy-patients 2025-04-05T10:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-milestone-pharmaceuticals-etripamil-nasal-spray 2025-04-05T07:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-in-alzheimer-s-disease-mayo-clinic-expert-outlines-future-of-targeted-treatments 2025-04-05T07:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-halts-medicare-and-medicaid-coverage-for-anti-obesity-medications 2025-04-05T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/antag-therapeutics-launches-first-in-human-trial-of-novel-gipr-antagonist-for-obesity-treatment 2025-04-05T02:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-appoints-dr-sanjay-keswani-as-new-chief-medical-officer 2025-04-05T02:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-drug-use-rapidly-declines-following-withdrawal-of-fda-accelerated-approval 2025-04-05T01:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-drug-studies-due-to-data-falsification-by-indian-cro-raptim-research 2025-04-05T01:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-to-present-promising-phase-2b-data-for-novel-als-drug-primec-at-aan-meeting 2025-04-04T22:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-workforce-reduction-creates-new-challenges-for-drug-development-programs 2025-04-04T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-designation-to-neo100-for-aggressive-childhood-brain-cancer 2025-04-04T22:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/tr1x-secures-8-million-cirm-grant-to-advance-novel-cell-therapy-for-graft-versus-host-disease 2025-04-04T19:38:51+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-arv-102-shows-promising-brain-penetration-and-lrrk2-reduction-in-first-in-human-parkinson-s-trial 2025-04-04T19:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nk-cell-therapy-with-bispecific-antibody-shows-93-response-rate-in-refractory-lymphoma 2025-04-04T19:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-licenses-nurix-s-novel-transcription-factor-program-for-autoimmune-disease-treatment 2025-04-04T16:38:54+00:00 hourly 0.9 https://trial.medpath.com/news/tremfya-becomes-first-il-23-inhibitor-to-reduce-structural-damage-in-psoriatic-arthritis 2025-04-04T16:38:12+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-cathay-capital-launch-275m-fund-for-clinical-stage-drug-innovation-in-china 2025-04-04T16:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/former-acting-fda-commissioner-delayed-novavax-vaccine-approval-raising-regulatory-concerns 2025-04-04T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-launches-cohealyx-new-collagen-based-dermal-matrix-accelerates-wound-healing 2025-04-04T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/gland-pharma-secures-usfda-approval-for-acetaminophen-injection-for-pain-management 2025-04-04T13:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/orthocell-secures-fda-clearance-for-remplir-nerve-repair-device-targeting-1-6-billion-us-market 2025-04-04T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-secures-eu-approval-for-datroway-in-breast-cancer-treatment 2025-04-04T11:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/vividion-therapeutics-initiates-phase-i-trial-of-novel-ras-pi3ka-inhibitor-for-advanced-solid-tumors 2025-04-04T11:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-first-anti-viral-drug-trial-for-long-covid-treatment 2025-04-04T10:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-advances-novel-gene-therapy-for-knee-osteoarthritis-with-first-patient-dosed-in-phase-2-trial 2025-04-04T10:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/accustem-s-msc-blood-test-set-to-transform-lung-cancer-screening-in-the-us 2025-04-04T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-launches-novocare-r-pharmacy-offering-authentic-wegovy-r-at-499-monthly 2025-04-04T03:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/patient-reported-physical-function-predicts-daratumumab-efficacy-in-multiple-myeloma-patients 2025-04-04T02:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/new-six-month-bpalm-regimen-shows-promise-for-drug-resistant-tb-patients-in-india 2025-04-04T01:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-trial-demonstrates-safety-of-targeted-therapy-for-deadly-childhood-brain-tumor-dipg 2025-04-04T01:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/nih-backed-ai-tool-reduces-hospital-readmissions-for-opioid-use-disorder-by-47 2025-04-04T01:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/3d-cell-culture-market-set-to-reach-3-48-billion-by-2028-as-pharma-industry-embraces-advanced-in-vitro-models 2025-04-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aiml-secures-2-17-million-in-oversubscribed-private-placement-for-ai-healthcare-innovations 2025-04-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-biotech-firms-surge-in-global-oncology-licensing-deals-commanding-30-billion-in-2024 2025-04-03T23:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/siemens-acquires-dotmatics-for-5-1-billion-to-enhance-ai-capabilities-in-life-sciences 2025-04-03T22:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/edgewise-therapeutics-faces-regulatory-and-safety-setbacks-across-multiple-drug-programs 2025-04-03T22:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/uplizna-becomes-first-fda-approved-treatment-for-igg4-related-disease-reducing-flare-risk-by-87 2025-04-03T22:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-histotripsy-cancer-treatment-trials-to-begin-in-singapore-by-2025 2025-04-03T22:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/brca2-mechanism-reveals-why-parp-inhibitors-work-in-only-some-cancer-patients 2025-04-03T20:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-discontinues-tigit-inhibitor-ociperlimab-after-phase-iii-trial-failure-prediction 2025-04-03T19:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/pharmamar-expands-global-reach-of-zepzelca-with-argentina-approval-and-merck-partnership-for-japan 2025-04-03T19:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/onesource-specialty-pharma-positions-for-major-growth-as-semaglutide-patent-expires-in-2026 2025-04-03T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/domain-therapeutics-to-showcase-novel-gpcr-targeting-oncology-programs-at-aacr-2025 2025-04-03T17:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/buntanetap-shows-promise-for-parkinson-s-patients-with-mild-dementia-in-phase-iii-trial 2025-04-03T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-minovia-s-ind-for-phase-ii-trial-of-novel-mitochondrial-therapy-in-fatal-pediatric-disease 2025-04-03T16:35:16+00:00 hourly 0.9